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I. INTRODUCTION 
What is IPF? 
Idiopathic pulmonary fibrosis (IPF) is a 
severe form of interstitial lung disease (ILD) 
characterized by progressive dyspnea, exercise 
intolerance, hypoxemia, and respiratory failure 
(1). The pathological equivalent of IPF, known as 
usual interstitial pneumonia (UIP), is identified by 
the presence of patchy areas of fibrotic remodeling 
in the distal lung parenchyma with fibroblastic 
foci (1-3) (Figure 1). Collagen deposition occurs 
in association with accumulation of activated 
(myo)fibroblasts in areas subjacent to the 
epithelial surface, which can be composed of 
hyperplastic type II alveolar epithelial cells 
(AECs) or epithelium with bronchiolar appearance 
(4). Collapse of remodeled alveoli creates focal areas of fibrosis and stretches adjacent lung 
parenchyma, resulting in micro-honeycombing and traction bronchiectasis, which are 
characteristic of this disorder.  In addition to AECs and fibroblasts, inflammatory cells are thought 
to contribute to the development of fibrosis (5). Specifically, macrophages with the M2 phenotype 
are found within parenchymal areas in IPF and secrete mediators that can impact fibrosis (5, 6). 
The current paradigm to explain IPF is that repetitive epithelial injury, along with genetic factors, 
results in persistent fibroblast activation and ongoing collagen and matrix deposition. 
Figure 1. Hematoxylin and eosin 
(H&E) stained section from a lung 
biopsy showing findings of usual 
interstitial pneumonia (UIP). Hallmark 
findings of UIP are noted, including areas 
of dense fibrosis (white arrow) adjacent to 
areas of normal lung (striped arrow), 
fibroblastic foci (black arrow), and 
hyperplastic epithelial cells lining areas of 
fibrotic remodeling (black arrowhead). 
Adapted from Idiopathic Pulmonary 
Fibrosis: A Disorder of Epithelial Cell 
Dysfunction, Zoz et al., Am J Med 
Sci.;341(6):435-8, Copyright (2011), 
with permission from Elsevier. 
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The burden of IPF: an unmet medical need  
IPF is a chronic, progressive, and irreversible lung disease. The prognosis of IPF is poor 
with median survival for patients being 3 - 5 years from the time of diagnosis (7). The prevalence 
of IPF ranges from 14 – 63 cases/100,000 people (8) and it leads to 30,000-50,000 deaths in the 
US every year (9). The mean age of onset for the disease is 65 years (10) and it is more common 
in men compared to women (11). Despite increasing efforts to understand disease pathogenesis 
and the performance of numerous clinical trials especially over the last two decades, treatment 
options for patients are limited. In 2014, Food and Drug Administration (FDA) approved the use 
of two antifibrotic agents, nintedanib and pirfenidone, for management of IPF (12); however, while 
these drugs may slow down disease progression, IPF remains an incurable disease. Due to absence 
of effective drugs, lung transplantation often becomes the only viable treatment option for IPF 
patients. Unfortunately, the 1- and 5-year survival rates for lung transplantation are the poorest 
compared to transplantation of any other solid organ (13). Additionally, from an economic 
standpoint, a 2012 study reviewing US claims database reported that the total direct cost for 
patients with IPF was $26,000/person-year and the incremental cost over control subjects was 
$12,124 (14). Taken together, it is clear that IPF poses a huge clinical and economic burden making 
it incumbent to advance our understanding of the pathophysiology of the disease to be able to 
develop effective therapeutic strategies.  
Pathogenesis of IPF: dysfunction of the alveolar epithelium  
Multiple lines of evidence implicate AEC dysfunction as pivotal in IPF (3).  In IPF lung 
biopsies, epithelial abnormalities are common and include hyperplastic AECs lining areas of 
honeycombing (15).  Although the critical mechanisms by which AECs contribute to IPF are 
incompletely understood, AEC apoptosis has been implicated in lung fibrosis based on human 
3 
disease and animal models (16).  Furthermore, AECs produce key pro-fibrotic mediators that are 
implicated in lung fibrosis (17) . 
The current body of literature suggests that a combination of genetic and environmental 
factors produce a vulnerable type II AEC population (18). On encountering recurrent or persistent 
injurious stimuli, the vulnerable type II AECs exhibit aberrant behavior including enhanced 
apoptosis and increased expression of pro-fibrotic mediators; ongoing dysfunction of type II AECs 
impairs normal injury-repair responses and leads to failed re-epithelialization, fibroblast 
activation, excessive extracellular matrix (ECM) deposition, and progressive fibrosis. One of the 
ways in which genetic and environmental factors can affect AEC phenotype is by inducing ER 
stress, and increasing evidence now implicates endoplasmic reticulum (ER) stress in AECs as 
important in IPF pathogenesis (19-22) (Figure 2). 
 
Figure 2. Potential mechanism of IPF pathogenesis. Adapted/modified from Genetic studies 
provide clues on the pathogenesis of idiopathic pulmonary fibrosis, Kropski JA, Dis Model 
Mech. 2013;6(1):9-17. 
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Endoplasmic reticulum stress as a pathogenic mechanism in lung fibrosis 
The ER is a specialized organelle responsible for maintaining protein homeostasis or 
‘proteostasis’. The ER is primarily required for protein folding and performing quality control of 
proteins before they reach their intracellular or extracellular destinations. Any condition that 
perturbs protein processing can lead to accumulation of misfolded proteins in the ER – a condition 
termed ER stress (Figure 3). In response to ER stress, the cell launches a signaling cascade termed 
the unfolded protein response (UPR). The UPR initially aims to restore proteostasis but may result 
in cell death under prolonged or severe ER stress (20). Chronic ER stress is a key contributor to 
numerous diseases including neurodegeneration, diabetes, cancer, and metabolic diseases (23). 
Current evidence points to a critical pathogenic role of ER stress/UPR in fibrosis in a number of 
organs, including kidney, heart, liver, gastrointestinal tract, and lung (21). Potential mechanistic 
links between ER stress and lung fibrosis were first identified >15 years ago with the discovery 
that familial IPF can be caused by mutations in surfactant protein C (SFTPC), which is produced 
by type II AECs (24-26). When mutant SFTPC constructs were expressed in lung epithelial cell 
lines, the result was accumulation of mutant protein in ER and induction of ER stress (27-32). 
Subsequently, immunohistochemistry studies from our group (27) and others (33) showed that ER 
stress markers are common in the lungs of patients with both familial and sporadic IPF and are 
primarily localized to hyperplastic type II AECs in areas of fibrotic remodeling. 
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Figure 3. Schematic illustration of endoplasmic reticulum (ER) stress. On accumulation of 
unfolded or misfolded proteins in the ER, BiP is released from the three ER stress sensors and 
becomes bound to the proteins instead; release of BiP activates the three sensors, and together 
they launch a cell signaling network called the unfolded protein response or UPR. 
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The unfolded protein response (UPR) pathway: an overview 
A cell produces up to 4 x 106 proteins every minute with the ER bearing the responsibility 
of folding and processing at least a third of those (34, 35). Functions of the ER include 
orchestrating biogenesis, folding, assembly, and trafficking of proteins, as well as degradation of 
defective proteins (36-39). ER function is tightly regulated by a combination of factors including 
protein load, metabolic demands of the cell, chaperone efficiency, redox balance, and calcium 
homeostasis (40-43). Perturbations in any of these factors can lead to ER stress and activation of 
the UPR.  
The UPR pathway consists of three ER transmembrane proteins: 1) PKR-like endoplasmic 
reticulum kinase (PERK), 2) activating transcription factor 6 (ATF6), and 3) inositol requiring 
enzyme 1  (IRE1α) (36). In an unstressed cell, binding immunoglobulin protein (BiP), which is 
a chaperone that facilitates protein folding remains bound to PERK, ATF6 and IRE1α, and 
maintains these sensors in an inactive state. In a stressed cell with accumulation of proteins in the 
ER, BiP is sequestered away from the sensors, resulting in their activation and initiation of the 
UPR, which is designed to restore cellular homeostasis through reduction in overall protein 
translation along with selective increases in expression of critical chaperone and redox proteins 
(44, 45) (Figure 4).  
PERK: On sensing ER stress, PERK is activated and undergoes auto-phosphorylation and 
dimerization (46). PERK then phosphorylates the α subunit of eukaryotic translation initiation 
factor 2α (eIF2α) at Ser51, which is the only known direct target of PERK (47). Phosphorylation 
of eIF2α leads to overall inhibition of protein synthesis. Phospho-eIF2α, however, can selectively 
up-regulate activating transcription factor 4 (ATF4), which is a transcription factor that induces 
expression of a set of genes required for cellular homeostasis (47-51). ATF4 can also activate 
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expression of pro-apoptotic factors, including growth arrest and DNA damage-inducible protein 
34 (GADD34) (48, 52) and C/EBP homologous protein (CHOP) (53, 54).  
 ATF6: After its release from BiP, ATF6 translocates to the Golgi where it is cleaved into 
amino terminal and carboxy terminal (cytosplasmic) domains by site1 and site2 proteases (55, 56). 
Cleaved cytoplasmic ATF6 then translocates to the nucleus where it activates transcription of 
several chaperones proteins, such as BiP, calreticulin, and protein disulphide isomerase (PDI) (57). 
Activated ATF6 also induces the expression of X-box binding protein 1 (XBP1), a downstream 
transcription factor activated through the IRE1α pathway (58, 59). 
 IRE1α: When released from chaperone binding, IRE1α undergoes oligomerization and 
auto-phosphorylation, resulting in activation of an RNase domain that cleaves XBP1 into an active 
form. Spliced XBP1 (XBP1s) then activates expression of target genes, including ER degradation 
enhancing -mannosidase like protein (EDEM), which promotes protein degradation through the 
ER-associated degradation (ERAD) pathway (60). In some settings, IRE1α can be activated to 
degrade a wider range of ER-localized mRNAs through a process known as IRE1α-dependent 
decay of mRNA (RIDD), thus affecting cell survival and other cellular phenotypes (61, 62). 
Figure 4. Schematic 
illustration of the UPR. 
ATF = activating 
transcription factor; BiP = 
immunoglobulin heavy-
chain-binding protein; 
EDEM = ER degradation 
enhancing α-mannosidase-
like protein; eIF2α = 
eukaryotic initiation factor 
2α; ER = endoplasmic 
reticulum; GADD34 = 
growth arrest and DNA 
damage protein 34; IRE =  
8 
 
 
 
 
 
 
 
Factors influencing ER stress 
In addition to genetically determined expression of mutant proteins, ER stress can be 
induced by: 1) exogenous factors that increase protein expression (e.g. viral infections) or produce 
reactive oxygen species (ROS) and/or impair redox balance in cells (e.g. cigarette smoke, inhaled 
particulates), and 2) intracellular processes that impair bioenergetics (e.g. hypoxia, aging), cause 
calcium shifts (e.g. mechanical stretch), or reduce clearance of misfolded proteins (e.g. 
proteasomal dysfunction, impaired autophagy) (Figure 5). 
Figure 5. Potential causes of ER stress. Adapted from Burman A, Matrix Biology. 2018; 68-
69:355-365 
inositol-requiring enzyme 1 (IRE-1); PERK = PKR-like ER kinase; XBP1 = X-box binding 
protein 1; GADD34 = growth arrest and DNA damage-inducible protein; PDI = protein 
disulphide isomerase; GRP94 = glucose-regulated protein 98; CHOP = C/enhancer binding 
protein (EBP) homologous protein; ASK1 = apoptosis signal-regulating kinase 1; JNK = c-Jun 
N-terminal kinases; S1P = site-1 protease; S2P = site-2 protease; RIDD = regulated IRE1-
dependent decay. Adapted/modified from Endoplasmic reticulum stress as a pro-fibrotic 
stimulus, Tanjore et al., Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 
1832(7):940-947., Copyright (2013), with permission from Elsevier. 
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In IPF, several groups have detected herpesvirus antigens in lungs of patients by 
polymerase chain reaction (PCR) and immunohistochemistry (63). Our group has reported 
concomitant expression of herpesvirus antigens and ER stress markers in AECs in IPF patients 
(27) as well as in asymptomatic relatives of patients with familial IPF (64), thereby suggesting a 
role of herpesvirus-induced ER stress in lung fibrosis. Also, increased expression of a repertoire 
of hypoxia-inducible genes has been reported in IPF lungs (65, 66) and in single cell analysis of 
AECs in IPF (67) supporting the existence of cellular hypoxia, which can induce ER stress (68).  
Aging represents another ER stress-influencing factor in patients with IPF, whose median age of 
diagnosis is 65 years (8, 69). Aging can significantly impair ER function through reduction in 
chaperone production, increase in dysmorphic mitochondria (impacting bioenergetics), and 
inefficient proteasomal degradation of proteins (70-73). Torres-Gonzalez et al. reported increased 
ER stress markers in type II AECs in old mice compared to young mice in an experimental model 
of lung fibrosis, thus supporting a connection between ER stress and aging (74). In addition to 
direct effects of aging, impairment in ER quality control mechanism (e.g. ERAD, autophagy) can 
contribute to ER stress (75, 76). In this regard, staining for microtubule-associated protein 1A/1B-
light chain 3-II (LC3-II), which is reflective of autophagy, was shown to be absent in type II AECs 
in fibrotic lesions while expression was prominent in non-fibrotic areas (76). 
Regulation of effector pathways by ER stress 
ER stress and UPR signaling have been linked to fibrosis through apoptotic cell death, 
activation/differentiation of fibroblasts, epithelial-mesenchymal transition (EMT), and activation 
or polarization of inflammatory responses (20, 21, 77). 
Epithelial cell apoptosis is a key component of fibrotic diseases in a number of organs, 
including the lungs (4, 20). Prolonged or excessive ER stress can induce apoptosis in epithelial 
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cells through several UPR-dependent downstream mechanisms, including induction of CHOP, 
activation of the ER bound caspase (caspase-4 in humans, caspase-12 in mice), or activation of c-
Jun NH2 terminal kinase (JNK) (36-38, 43). Of these three pathways, apoptosis through induction 
of CHOP is best studied. CHOP is a member of the C/EBP family of transcription factors. It 
functions both as an inhibitor of C/EBP transcriptional activity and an inducer of gene targets 
through interactions with alternative enhancer sites (78, 79). CHOP regulates the apoptotic 
pathway through activation of pro-apoptotic genes and downregulation of anti-apoptotic genes, 
such as B-cell lymphoma 2 (BCl2) (80). In most reports, CHOP is primarily induced downstream 
of PERK/ATF4, but all 3 arms of the UPR can participate in CHOP induction (81). ER stress can 
also cause apoptosis through UPR-independent cell death mechanisms. For example, excessive 
ER stress releases calcium into the cytosol, which can trigger apoptosis through Bcl2-associated 
X protein (Bax) and Bcl2 homologous antagonist killer (Bak) (82). 
In addition to effects on cell survival, ER stress can affect cell differentiation. In this regard, 
XBP1 contributes to plasma cell differentiation (83). In the context of fibrosis, ER stress has been 
shown to affect differentiation of fibroblasts to myofibroblasts, which are an activated subset of 
fibroblasts common in fibrotic diseases that produce large amounts of collagen and other 
extracellular matrix components. For example, fibroblasts treated with ER stress-inducing agents 
are more susceptible to myofibroblast differentiation induced by transforming growth factor  
(TGFβ) (84, 85). In epithelial cells, ER stress has been shown to induce EMT, resulting in a cellular 
phenotype that may directly participate in fibrotic remodeling (31, 32). In addition to in vitro 
studies showing ER stress-induced EMT, treatment of mice with cyclosporine, which can induce 
ER stress in renal tubular epithelial cells, has been shown to cause EMT through both TFGβ 
dependent and independent mechanisms (86, 87). 
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Inflammation is linked to fibrosis in a number of organs, including lungs, and ER stress 
and the UPR pathway have been shown to regulate inflammatory signaling pathways, including 
nuclear factor kappa B (NF-κB) and activator protein-1 (AP-1) (88). In inflammatory bowel 
disease, ER stress has been observed in colonic mucosa and the IRE1α pathway has been shown 
to regulate disease progression (89). Accumulation of mutant muc2 (mucin in intestinal goblet 
cells) results in ER stress and inflammation in the large intestine with increased expression of 
interleukin-1β (IL-1β), tumor necrosis factor  (TNFα), and interferon-γ (90). In bone marrow 
derived macrophages subjected to LPS stimulation, ER stress is able to drive production and 
processing of pro–IL-1β (91). 
Macrophages can be polarized into M1 (pro-inflammatory) or M2 (pro-fibrotic) subsets 
based on microenvironmental stimuli (92). Based on available data, ER stress may be able to skew 
macrophage populations towards either a M1 or a M2 phenotype depending on the 
pathophysiological context. In obesity, IRE1 deficiency has been reported to favor the M2 
macrophage phenotype (93) and CHOP deficiency can increase both M1 and M2 macrophages 
(94). However, in diabetes, pulmonary fibrosis, and allergic airway inflammation, ER stress has 
been reported to drive M2 polarization through JNK or CHOP dependent mechanisms (95-97). 
 
 
 
 
 
 
 
12 
Pro-fibrotic effects of ER stress in individual lung cell types in lung fibrosis 
Pro-fibrotic effects of ER stress may be transduced through several different cell types in 
the lungs, including alveolar epithelial cells, fibroblasts, and macrophages (Figure 6). The impact 
of ER stress on pro-fibrotic characteristics of each of these cell types is discussed below. 
 
Alveolar epithelial cells:  
In lungs of IPF patients, ER stress markers have been identified primarily in type II AECs 
(27, 33). By immunohistochemistry, we identified increased expression of BiP, EDEM, and XBP1 
in AECs from patients with both familial and sporadic IPF (27). In addition, Korfei et al. reported 
increased expression of ATF4, ATF6, and CHOP in AECs from lung sections obtained from IPF 
patients, along with evidence of apoptosis by immunostaining for cleaved caspase 3 (33).  
Figure 6. Pro-fibrotic effects of ER stress in different cell types in lung fibrosis. Adapted 
from Burman A, Matrix Biology. 2018; 68-69:355-365 
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In type II AEC lines, over-expression of mutant SFPTC genes (either exon 4 deleted or 
L188Q SFTPC) results in ER stress and increased apoptosis (27, 29, 30).  Constitutive expression 
of exon 4 deleted SFTPC in mice resulted in fetal lethality with disrupted lung morphogenesis and 
defective surfactant protein processing (98). We generated doxycycline inducible transgenic mice 
in which mutant L188Q SFTPC is expressed in type II AECs (99). When this transgene was 
induced in type II AECs or when the ER-stress inducing agent tunicamycin was administered 
through direct intratracheal instillation into the lung, ER stress was observed in type II AECs; 
however, fibrosis did not develop, and AEC apoptosis was not identified. In contrast, treatment 
with low dose bleomycin resulted in a substantial increase in fibrosis with greater AEC apoptosis 
than treatment with bleomycin alone (99). Together, these data indicate that ER stress in AECs is 
not sufficient to induce lung fibrosis. Rather, ER stress appears to sensitize to development of 
fibrosis following epithelial injury.   
The mechanisms by which ER stress regulates survival/apoptosis of AECs are 
incompletely understood and may be context dependent. In cultured type II AECs over-expressing 
mutant forms of SFTPC, Mulegeta et al. identified caspase 4/12 as an important mediator of 
apoptosis (30). Similarly, activation of caspase-12 and cleaved caspase-3 were detected in lungs 
of mice expressing L188Q SFTPC in type II AECs following bleomycin treatment (99). CHOP 
has also been implicated in ER stress-dependent AEC apoptosis (33) although prior studies show 
inconsistent effects of CHOP deletion on lung fibrosis. Tanaka et al. (100) reported that CHOP 
deficient mice have reduced AEC apoptosis and lung fibrosis after bleomycin treatment. In 
contrast, Ayaub et al. (101) found that CHOP deficient mice had higher mortality and increased 
fibrosis compared to wild-type controls following bleomycin treatment.  
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Several other mechanisms have been implicated in ER stress-induced AEC apoptosis, 
including regulation of ER Ca2+. Calmodulin-dependent kinase II (CAMKII) is an important 
regulator of ER Ca2+ and can modulate apoptosis (102). Inhibition of CAMKII using transgenic 
mice with AEC specific expression of the CaMKII inhibitor peptide AC3-I resulted in decreased 
intracellular Ca2+, reduced CHOP, decreased AEC apoptosis, and protection from fibrosis 
following bleomycin treatment (102).  In addition, Bueno M. et al. (72) showed that the 
mitochondrial protective factor PTEN-induced putative kinase 1 (PINK1) is decreased in IPF 
lungs.  In experimental models, ER stress induction resulted in decreased PINK1 in AECs, along 
with altered bioenergetics and increased AEC apoptosis (72). PINK1 loss can also induce ER 
stress, indicating the possibility of a feedback mechanism linking ER stress, mitochondrial 
dysfunction, and fibrotic remodeling (103). 
In addition to AEC apoptosis, another possible mechanistic link between ER stress and 
fibrosis comes from studies in which ER stress-inducing agents or expression of mutant SFTPC 
were shown to induce EMT in AECs with increased expression of mesenchymal markers such as 
 smooth muscle actin (αSMA), vimentin, N-Cadherin and reduction of epithelial markers like E-
Cadherin, and zona occludens-1 (ZO-1) (31, 32). Further studies suggested the IRE1α/XBP1 
pathway is critical for regulating EMT in type II AECs (31).  Along these lines, induction of ER 
stress due to expression of mutant SFTPC (exon4 deletion) in A549 cells increased collagen 
production and secretion (104). 
Fibroblasts: 
Myofibroblast differentiation is involved in wound healing and is characteristic of fibrotic 
diseases since these activated myofibroblasts produce increased amounts of collagen and matrix 
components (105). In fibroblasts from IPF patients, pharmacological inhibition of ER stress 
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through 4-phenylbutyric acid (4-PBA) treatment reduced TGFβ1-induced myofibroblast 
differentiation, αSMA expression, and collagen production (84). Knockdown of the ER chaperone 
calreticulin using siRNA in mouse and human IPF fibroblasts reduced TGFβ1-induced collagen 
and fibronectin production (106). Similarly, treatment of fibroblasts with an IRE1α inhibitor 
reduced collagen 12 and fibronectin expression and reduced autophagy in IPF lung fibroblasts 
following TGFβ treatment (85).  In addition, ER stress regulation of PI3K/AKT signaling has been 
implicated in fibroblast proliferation and differentiation (107). Together, current data implicate ER 
stress in regulating myofibroblast differentiation in the lungs; however, whether this is a critical 
pathogenic mechanism in IPF remains to be determined.  
Macrophages: 
Macrophages can contribute to lung fibrosis through secretion of pro-fibrotic mediators 
(e.g. TGF), chemokines, and matrix metalloproteases (5, 108, 109). In the lungs, ER stress has 
been reported in macrophages obtained by bronchoalveolar lavage from asbestosis patients and 
alveolar macrophages from mice with asbestos-induced lung fibrosis (110). In IPF, Yao et al. 
reported expression of CHOP in M2 macrophages in IPF patients (96). 
Several groups have shown that ER stress can affect macrophage phenotypes; however, 
current studies are inconsistent regarding the impact of ER stress on M2 macrophage polarization. 
In mouse obesity models, genetic deficiency of IRE1α or CHOP resulted in increased M2 
macrophages (93, 94). On the other hand, several studies have shown that induction of ER stress 
skews towards M2 polarization. Specifically, ER stress-induced JNK activation has been shown 
to induce M2 polarization in mouse peritoneal macrophages (95). In lung macrophages, CHOP 
has been reported to induce M2 polarization in the bleomycin model of pulmonary fibrosis and a 
model of allergic airway inflammation (96, 97). Similarly, treatment of murine bone marrow-
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derived macrophages with PBA was reported to prevent palmitate-induced M2 polarization (111). 
Although available studies suggest that the effects of ER stress on macrophage polarization depend 
on the disease context, ER stress in lung macrophages appears to favor the M2 phenotype. 
In addition to effects on macrophage polarization, ER stress may impact fibrosis by 
inducing macrophage apoptosis, thereby abrogating the effects of M2 polarization. Ayaub et al. 
showed that CHOP expression induced macrophage apoptosis and protected from bleomycin-
induced lung fibrosis (101). Similarly, silica has been shown to induce alveolar macrophages 
apoptosis via ER stress in vitro (112). Taken together, these data reveal a complex interplay 
between ER stress and macrophage phenotype. Further studies are needed to clarify whether the 
net effect of ER stress in macrophages is pathogenic or protective in different models of lung 
fibrosis. 
C/EBP homologous protein (CHOP) 
 Over the past few years, several studies have reported a role of CHOP in lung fibrosis. 
CHOP, also known as growth arrest and DNA damage inducible gene 153 (GADD153), is a 
member of the C/EBP family of transcriptions factors and is a primary mediator of ER stress-
induced apoptosis. It is a 29 kDa protein comprising of 169 amino acids in humans and 168 amino 
acids in rodents. CHOP is ubiquitously expressed at low levels in homeostatic conditions while 
cellular stress (e.g. ER stress, amino acid starvation) leads to increased expression of CHOP and 
its accumulation in the nucleus (113).  
CHOP can act both as a dominant negative inhibitor of other members of the C/EBP family 
and as a transcription factor. Specifically, CHOP heterodimerizes with other members of the 
C/EBP family, which have a strong preference for homodimerization; while CHOP-C/EBP 
heterodimers cannot bind to the consensus C/EBP site on the promoters of target genes, these 
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heterodimers can bind to a unique site on a unique set of target genes and activate them. CHOP 
consists of an N-terminal transcriptional activation domain and a C-terminal basic leucine zipper 
(bZIP) domain responsible for DNA binding and dimerization (113) (Figure 7).  
 
 
 
 
  
 
 CHOP is primarily regulated at the transcriptional level. The human CHOP promoter 
contains two amino acid regulatory element (AARE) and at least two ER stress-response element 
(ERSE) cis-acting motifs. On induction of ER stress, the upstream ER stress mediators ATF4, 
ATF6, and XBP1 bind to these motifs on the CHOP promoter and induce expression of CHOP; 
specifically, ATF4 binds to the AARE1 and AARE2 motifs whereas ATF6 and XBP1 bind to the 
ERSE1 and ERSE2 motifs.  While all the three UPR pathways namely PERK/ATF4, ATF6 and 
IRE1/XBP1 are required for maximal induction of CHOP, it has been shown that the PERK/ATF4 
pathway is essential for CHOP induction in ER stress and dominates over the ATF6 and 
IRE1/XBP1 pathways (113).  
Figure 7. Domain structure of human CHOP. CHOP is composed of its N-terminal putative 
transactivation domain and a C-terminal bZIP domain that contains a DNA-binding basic 
region and a leucine zipper dimerization region. The basic region contains conserved glycine 
(109) and proline (112) residues, which are essential for binding to the unique CHOP binding 
site on target genes. Two serine residues (79 and 82) in the transactivation domain are 
phosphorylated by p38 MAP kinase, and this phosphorylation is required for the enhanced 
transcriptional activation. Adapted with permission from Springer Nature: Nature, Cell Death 
and Differentiation, Roles of CHOP/GADD153 in endoplasmic reticulum stress, Oyadomari S, 
Cell Death Differ. 2003;11(4):381-9, Copyright (2003). 
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CHOP has been implicated in diseases such as diabetes and neurodegenerative disorders 
where enhanced apoptosis may contribute to the disease process. Overexpression of CHOP leads 
to apoptosis in cells and CHOP deficient cells have reduced ER stress-induced apoptosis. As a 
transcription factor, CHOP can regulate the expression of numerous apoptosis-related genes 
including DOCs (down-stream of CHOP), B-cell lymphoma-2 (BCl-2), tribbles-related protein3 
(TRB3), and growth and DNA damage 34 (GADD34) (114).  
Hypoxia and fibrosis 
 Hypoxia is a common factor in the microenvironment of injured/damaged tissue in fibrosis 
in several organs (115). Following tissue damage, an imbalance created by decreased oxygen 
supply (due to compromised perfusion) and increased oxygen demand (due to infiltration of 
inflammatory and mesenchymal cells) may lead to tissue hypoxia. While transient hypoxia often 
helps in tissue repair, chronic hypoxia may be maladaptive and promote excessive scarring (115). 
Chronic hypoxia has been implicated as a pathogenic factor in kidney, liver, and heart fibrosis 
(116-118). In the lungs, hypoxia is known to contribute to vascular remodeling in pulmonary 
hypertension (119); however, the role of tissue hypoxia in lung fibrosis is unclear. Mechanistically, 
in addition to induction of ER stress, studies have suggested a potential role of hypoxia in several 
cellular processes including inflammatory pathways, expression of pro-fibrotic mediators, 
secretion of collagen, oxidative stress, EMT, and apoptosis (120-126). Taken together, tissue 
hypoxia is a potentially pathogenic microenvironmental factor that needs to be considered while 
investigating the pathophysiology of fibrosis.   
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Hypoxia-inducible factor (HIF) signaling 
 The cellular responses to hypoxia occur primarily through signaling via the hypoxia 
inducible factors, HIF1 and HIF2. The stability of HIF1 and HIF2 is determined by the 
availability of oxygen. In normoxia, HIF1 and HIF2 are hydroxylated at specific proline 
residues by prolyl hydroxylases, which leads to their subsequent ubiquitination and degradation. 
In hypoxia, lack of oxygen inhibits the activity of prolyl hydroxylases leading to stabilization of 
HIF1 and HIF2. These isoforms of HIF are then transported to the nucleus where they dimerize 
with the ubiquitously expressed subunit HIF1 and form transcriptionally active HIF1 or HIF2. 
HIFs bind to hypoxia response element (HRE) on promoters of specific target genes and activate 
them (127) (Figure 8).   
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HIF signaling has been implicated in tissue repair and fibrosis in several organs (116, 117). 
For example, targeted deletion of HIF1α in the renal tubular epithelium was shown to attenuate 
kidney fibrosis following unilateral ureteral obstruction (128). Similarly, reduced liver fibrosis was 
Figure 8. Regulation of HIF-1 stability and activity is oxygen-dependent. In normal 
oxygen tension, HIF-1 undergoes two prolyl hydroxylations within its degradation 
domain by PHD-2 and PHD-3, enabling its interaction with VHL protein. VHL functions 
as the recognition component of an E3 ubiquitin ligase that targets HIF-1 for 
ubiquitination (Ub) and proteosomal degradation. In addition, FIH acts as an asparaginyl 
hydroxylase, leading to asparaginyl hydroxylation within the C-transactivation domain of 
HIF-1 and preventing interaction of HIF-1 with various coactivators, such as p300/CBP, 
thus resulting in its inactivation. During hypoxia, activity of the prolyl and asparaginyl 
hydroxylases, which is oxygen-dependent, is markedly reduced. The accumulating HIF-
1 combines with HIF-1 to form a heterodimer that binds to DNA and interacts with its 
coactivators p300/CBP, driving transcription of various HIF-1 inducible genes. Adapted 
from Tal et al., The Role of Hypoxia and Hypoxia-Inducible Factor-1 Alpha in 
Preeclampsia Pathogenesis, Biology of Reproduction, 2012;134:1-8 by permission of 
Oxford University Press.  
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observed in HIF1 deficient mice in a bile-duct ligation model (129), and HIF2 has been shown 
to regulate hepatic fibrogenesis in the setting of steatohepatitis (130). Also, HIF1 has been 
reported to induce fibrogenesis in white adipose tissue (131). HIFs may impact tissue fibrosis in 
various ways including effects on pro-fibrotic mediators, cell survival, cell migration, 
inflammation, and angiogenesis (119, 132).  
In conclusion, research over the last two decades has established that injury and 
dysfunction of type II AECs are critical in the pathogenesis of IPF. While available studies provide 
compelling evidence for ER stress in type II AECs in IPF, the etiology of ER stress in the vast 
majority of IPF lungs is unknown. In addition, the mechanisms by which ER stress contributes to 
fibrosis in the lungs have been challenging to unravel. Our studies described in Chapter III suggest 
hypoxia to be an etiological factor underlying ER stress observed in lung fibrosis and show CHOP 
to be a critical molecular mechanistic link between ER stress and lung fibrosis. Our work described 
in Chapter IV provides insight into the signaling pathways important in induction of CHOP and 
those in CHOP-mediated cell death in AECs in hypoxia. While HIF, a primary mediator of cellular 
responses to hypoxia, has been implicated in fibrosis in several organs, its role in lung fibrosis is 
not clear. Our investigations described in Chapter V focus on the role of HIF in two distinct mouse 
models of lung fibrosis and the effect of HIF signaling on phenotype of AECs. While Chapters III 
and IV of this dissertation have been published in JCI Insight (133) , Chapter V consists of both 
published (133) and unpublished work.  
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II. MATERIALS AND METHODS 
 
Human samples 
 Lung samples were obtained from surgical lung biopsies or explanted lung tissue obtained 
at the time of organ transplantation. Explanted donor lungs that were rejected for transplantation 
were used as controls. 
Mice 
 We used 8- to 10-week-old male and female mice for these experiments (C57BL/6J 
background). WT and CHOP–/– mice were purchased from The Jackson Laboratory. Doxycycline-
inducible transgenic mice that express a mutant form of human SFTPC (L188Q SFTPC) (99) 
driven by a murine SFTPC promoter construct were crossed with CHOP–/– mice to generate L188Q 
SFTPC/CHOP–/– mice. L188Q SFTPC mice were used as controls. HIF1α-floxed (128) and 
HIF2α-floxed (134) mice were crossed to generate HIF1α/HIF2α-floxed mice. Transgenic mice in 
which both HIF1α and HIF2α are deleted in the lung epithelium were generated by crossing the 
HIF1α/HIF2α-floxed mice with SPC.Cre.Rosa.STOP.LacZ mice, in which Cre recombinase 
expression is under the control of a 3.7-kb human SPC promoter as described previously (128, 
135-137). Mice with HIF1α/HIF2α deleted in lung epithelium were designated as HIFΔ/Δ. 
Littermate controls used were negative for Cre expression and designated as HIFfl/fl. Mice were 
housed in the animal care facility at the Vanderbilt University Medical Center and given food and 
water ad libitum.  
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Lung fibrosis models 
  Bleomycin (Hospira Inc.) was purchased from Vanderbilt University Medical Center 
pharmacy. Bleomycin (0.04 units or 0.08 units) in 100 μl saline was delivered by direct i.t. 
instillation under anesthesia as described previously (135, 137, 138). Mice were administered a 
single-dose or repetitive doses (6 doses at intervals of 2 weeks) of bleomycin, depending on the 
experimental strategy. Doxycycline-inducible transgenic mice were treated with doxycycline in 
drinking water (2 g/l) for 1 week prior to bleomycin instillation, and doxycycline was continued 
through the course of experiments. Lungs were harvested following euthanasia by exposure to 
carbon dioxide at designated time points. Right lungs were tied off and snap frozen for estimation 
of collagen and extraction of RNA and protein, and left lungs were inflated with 10% formalin for 
histology under constant pressure using a 25-cm pressure column as previously described (135). 
Exposure of mice to hypoxia 
 Mice were exposed to hypoxia in a normobaric hypoxia chamber (Biospherix), in which 
oxygen concentration is controlled through flow of nitrogen to achieve the desired FiO2. 
Ventilation ensures that carbon dioxide concentration remains below 1,000 parts per million. 
Detection of cellular hypoxia 
 Mice were treated with pimonidazole (60 μg/g body weight; HypoxyProbe Inc.) in 75 μl 
sterile normal saline by intraperitoneal (i.p.) injection at 3 hours prior to lung harvest. 
Subsequently, IHC for pimonidazole adducts was performed on lung sections. 
Morphometry 
 Left lungs were formalin-fixed, paraffin-embedded, sectioned, and stained with Masson’s 
trichrome as previously described (135, 137). Lung morphometry was performed as previously 
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described (135). For each lung sample, images were captured at ×4 using an Olympus BX81 
research microscope. Areas of fibrosis or hyperplastic cells were measured using Cell Sens 
Dimension (Olympus). 
IHC and immunofluorescence 
 IHC was performed on paraffin-embedded lung tissue sections as previously published 
(135, 137) using the following primary antibodies: pro-SPC (1:1,000 dilution, AB3786, 
MilliporeSigma), CHOP (1:300 dilution, SC-575, Santa Cruz Biotechnology), HIF1α (1:300 
dilution, SC-10790, Santa Cruz), pyruvate kinase (1:300 dilution, GTX107977, Genetex), CA-IX 
(1:300 dilution, NB100-417, Novus Biologicals), pimonidazole (biotin-conjugated antibody, 
Mouse-Biotin-Mab, HypoxyProbe Inc.). Primary antibodies were developed using Vectastain Elite 
anti-rabbit ABC peroxidase kits and Vectastain Elite antimouse ABC peroxidase kits (both from 
Vector Laboratories). Peroxidase substrate was developed with VECTOR NovaRED Peroxidase 
(HRP) Substrate Kit (Vector Laboratories). For quantification of CHOP, CHOP+ AECs (based on 
morphology and location) were counted in 10 high-power fields (HPFs) on each lung section. To 
detect cellular hypoxia in different cell types, dual immunofluorescence staining for pimonidazole 
adducts was performed with pro-SPC (1:1,000 dilution, AB3786, MilliporeSigma), S100A4 
(1:400 dilution) (139), T1α (1:500 dilution, 8.1.1, Developmental Studies Hybridoma Bank, Iowa 
City, Iowa, USA), CD34 (1:300 dilution, 119302, BioLegend), and F4/80 (1:300 dilution, 
MCA497G, AbD Serotec). For immunofluorescent detection of HIFs, HIF1 (1:300 dilution, SC-
10790, Santa Cruz) and HIF2 (1:200 dilution, NB100-122, Novus Biologicals) primary 
antibodies were used.  Following primary antibody incubation, appropriate fluorescent secondary 
antibodies (Jackson Immunoresearch) were used and nuclear counterstaining was performed using 
Vectashield mounting media with DAPI (Vector Laboratories). Dual fluorescent images were 
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captured using an Olympus IX81 Inverted Research Microscope configured with an Olympus IX2 
Biological Disk Scanning Unit (Olympus). Quantification of pro-SPC, pimonidazole, and dual-
positive cells was performed in 10 HPFs on each lung section 
Evaluation of cell death 
For evaluation of apoptosis in lung tissue, TUNEL staining was performed using the 
Fluorescent In Situ Cell Death Detection Kit (MilliporeSigma). The total number of TUNEL+ type 
II AECs (based on morphology and location) was quantified in 10 HPFs on each lung section as 
previously published (140). In addition, dual immunofluorescence was performed for TUNEL and 
pro-SPC, and double-positive cells were quantified in 10 HPFs on each lung section. To detect 
cytotoxicity in vitro, the lactate dehydrogenase (LDH) assay (Promega) was performed as per the 
manufacturer’s instructions. 
Measurement of collagen and fibronectin 
 Total soluble collagen in right lower lobes of the lung was measured using the Sircol assay 
(Biocolor; Accurate Chemical and Scientific Corporation) as per the manufacturer’s instructions 
and as previously published (141). Fibronectin in lung tissue was measured using the Mouse 
Fibronectin ELISA Kit (Abcam) as per the manufacturer’s instructions. 
Quantification of immune/inflammatory cell types by flow cytometry 
 Lungs were enzymatically digested using collagenase XI (MilliporeSigma) and DNase IV 
(Macs Miltenyi Biotec) for 45 minutes at 37°C to obtain single-cell suspensions, followed by 
incubation with viability dye (Thermo Fisher Scientific) for 20 minutes according to the 
manufacturer’s instructions. Cells were then incubated with anti-CD16/32 antibodies and further 
labeled with the following fluorescent dye–conjugated mAbs: CD45-efluor 650 (95-0451- 42, 
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eBioscience/Thermo Fisher Scientific), Ly6C-APC-Cy7 (128025, BioLegend), Ly6G-Alexa Fluor 
700 (127621, BioLegend), CD11b-APC (101212, BioLegend), CD11c-PE-Cy7 (25-01140-81, 
eBioscience/Thermo Fisher Scientific), F4/80-PE-Cy5 (123111, BioLegend), CD103-PE (12-
1031-81, eBioscience/Thermo Fisher Scientific), CD19-PE (12-0193-81, eBioscience/Thermo 
Fisher Scientific), and CD3-Alexa Fluor 488 (100321, BioLegend). Samples were acquired on an 
LSRII machine (BD Biosciences), and data were analyzed using FlowJo software. 
M1/M2 macrophage polarization 
 The M1 and M2 macrophage phenotype was determined as previously published (142). In 
brief, freshly isolated lungs were digested with collagenase XI (0.7 mg/ml; MilliporeSigma) and 
type IV bovine pancreatic DNase (30 mg/ml; MilliporeSigma) in RPMI-1640 media to obtain 
single-cell suspensions. Red blood cells (RBCs) were lysed in RBC Lysis Buffer (BioLegend), 
followed by adherence on 6-well culture plates for 2 hours. Cells were supplemented with RPMI-
1640 media with 10% FBS. Supernatant was discarded, mRNA was isolated from adherent 
macrophages, and qPCR was performed. The following primer sets were used: TNF-α — forward, 
5′-AAGCCTGTAGCCCACGTCGTA-3′, reverse, 5′-GGCACCACTAGTTGGTTGTCTTTG-3′; 
IL-6 — forward, 5′-TCCTCTGGTCTTCTGGAGTA-3′, reverse, 5′-
CTTAGCCACTCCTTCTGTGA-3′; IL-12p35 — forward, 5′-
TGGACCTGCCAGGTGTCTTAG-3′, reverse, 5′-CAATGTGCTGGTTTGGTCCC-3′; iNOS — 
forward, 5′-CACCTTGGAGTTCACCCAGT-3′, reverse, 5′-ACCACTCGTACTTGGGATGC-3′; 
IL-10 — forward, 5′-ATAACTGCACCCACTTCCCA-3′, reverse, 5′-
GGGCATCACTTCTACCAGGT-3′; arginase-1 — 5′-ATGGAAGAGACCTTCAGCTAC-3′, 
reverse, 5′-GCTGTCTTCCCAAGAGTTGGG-3′; Ym1 — forward, 5′-
GGGCATACCTTTATCCTGAG-3′, reverse, 5′-CCACTGAAGTCATCCATGTC-3′; mannose 
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receptor — forward, 5′-CAAGGAAGGTTGGCATTTGT-3′, reverse, 5′-
CCTTTCAGTCCTTTGCAAGC-3′; and GAPDH — forward, 5′-
TGAGGACCAGGTTGTCTCCT-3′, reverse: 5′-CCCTGTTGCTGTAGCCGTAT-3′. mRNA 
expression in each sample was normalized to GAPDH.  
Cell culture and hypoxia exposure 
  Mouse lung epithelial cells (MLE12) were purchased from ATCC. The cells were 
maintained in DMEM (Invitrogen, Life Technologies) with 2 mM L-glutamine, supplemented with 
FBS (10%) and antibiotics (100 units/ml penicillin and 100 μg/ml streptomycin). MLE12 cells 
were plated at 70%–80% confluence in 6-well plates. Twenty-four hours later, media were 
changed to fresh DMEM with FBS and antibiotics, and cells were exposed to hypoxia (1.5% O2) 
using an in vitro hypoxia chamber (Coy Laboratory) or normoxia (21% O2 ) for an additional 24–
48 hours.  
HIF reporter cells 
MLE12 cells were seeded at 70% confluency in 96 well plates. Cignal lenti HIF reporter 
was obtained from Qiagen. Cells were transfected with 10 multiplicity of infection (MOI) Lenti 
HIF reporter in antibiotic free conditions using SureENTRY™ Transduction Reagent (Qiagen) 
(5ug/ml) as per the manufacturer’s instructions. 24 hours after transfection, the cells were switched 
into medium containing 10% fetal bovine serum. Stable cells were generated using puromycin-
based (10µg/ml) selection. For measurement of HIF activity after hypoxia exposure, activity of 
firefly luciferase (that is indicative of HIF activity) was measured as relative light units (RLU) 
using the Dual-Luciferase Reporter Assay System (Promega). 
 
28 
siRNA studies 
 On-Target Smartpool siGenome siRNAs were used to target ER stress pathways and HIF1α 
in MLE12 cells as previously described (31). The following mouse constructs were used for siRNA 
targeting: IRE1α (L-041030-00), ATF4 (L-042737-01), HIF1α (L-040368-00), CHOP (L-062068-
00), and nontarget control (D-001210-04-05) (all from Dharmacon). In brief, MLE12 cells were 
plated at 40%–50% confluence in 6-well plates in DMEM with FBS but no antibiotics and cultured 
overnight in a standard cell culture incubator. Cells were transfected with 25 nM Smartpool siRNA 
using Lipofectamine RNAi Max (Life Technologies) as per the manufacturer’s instructions. 
Twenty-four hours later, the media were replaced with fresh DMEM (with FBS and antibiotics), 
and cells were exposed to hypoxia (1.5% O2) or normoxia (21% O2) for an additional 48 hours.  
Small molecule-mediated inhibition of UPR pathways 
 For chemical inhibition of IRE1α and PERK, MLE12 cells were plated at 70% confluence 
in 6-well plates in DMEM. Twenty-four hours later, media were replaced with 2 ml fresh DMEM 
in each well. 10 μM PCP-101 (Mannkind Corporation) or 0.3 μM GSK2606414 (MilliporeSigma) 
in DMSO was added to the treatment groups, and 2 μl DMSO (MilliporeSigma) was added to the 
vehicle control groups. 
Western blotting 
 Total protein extracts were prepared from lungs using RIPA lysis buffer with protease and 
phosphatase inhibitors (Life Technologies Corporation) as previously described (27, 31). The 
following primary antibodies were used: CHOP (1:300 dilution, SC-7351, Santa Cruz 
Biotechnology), PDI (1:1,000 dilution, C81H6, Cell Signaling), ATF4 (1:1,000 dilution, 10835-
1-AD, Proteintech Group Inc.), XBP1s (1:1,000 dilution, 658802, BioLegend), β-actin (1:25,000 
29 
dilution, A5316, MilliporeSigma), IRE1α (1:1,000 dilution, 14C10, Cell Signaling), ATF6 (1:500 
dilution, NB1-40256SS, Novus Biologicals), and HIF1α (1:500 dilution, NB-100-479, Novus 
Biologicals). Western blots were developed using corresponding fluorescent-conjugated IRDye 
secondary antibodies and the Odyssey Infrared Imaging System (LI-COR Biosciences). 
Densitometry was performed using ImageJ software (NIH), and band intensities were normalized 
to β-actin. 
RNA isolation and quantitative PCR 
Total mRNA was isolated from lung tissue or MLE12 cells using a RNeasy Mini kit 
(Qiagen) as per the manufacturer’s instructions. Following RNA isolation, DNA digestion was 
performed using the DNA-free DNA Removal kit (Ambion Thermo Scientific), and cDNA was 
synthesized using Superscript III Reverse Transcriptase (Invitrogen) or Superscript VILO Master 
Mix (Invitrogen) as per the manufacturer’s instructions. qPCR was performed using SYBR green 
PCR master mix (Applied Biosystems) as per the manufacturer’s instructions. The following 
primer sets were used: XBP1 spliced forward 5′-GAGTCCGCAGCAGGTG-3′ and XBP1 spliced 
reverse 5′-GTGTCAGAGTCCATGGGA-3′, XBP1 unspliced forward 5′-
GACTATGTGCACCTCTGCAG-3′ and XBP1 unspliced reverse 5′-
CTGGGAGTTCCTCCAGACTA-3′, ATF4 forward 5′-GGGTTCTGTCTTCCACTCCA-3′ and 
ATF4 reverse 5′-AAGCAGCAGAGTCAGGCTTTC-3′, CHOP forward 5′- 
CCACCACACCTGAAAGCAGAA-3′ and CHOP reverse 5′-AGGTGAAAGGCAGGGACTCA-
3′, HIF1α forward 5′-TGGAGATGCTGGCTCCCTAT-3′ and HIF1α reverse 5′-
TGGAGGGCTTGGAGAATTGC-3′, GADD45A forward 5′-TGCGAGAACGACATCAACAT-
3′ and GADD45A reverse 5′-TCCCGGCAAAAACAAATAAG-3′, ATF5 forward 5′-
GGCTGGCTCGTAGACTATGG-3′ and ATF5 reverse 5′CCAGAGGAAGGAGAGCTGTG-3′, 
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BNIP3L forward 5′-CCTCGTCTTCCATCCACAAT-3′ and BNIP3L reverse 5′-
GTCCCTGCTGGTATGCATCT-3′, CCN1 forward 5'-GGGTTGGAATGCAATTTCG-3' 
and CCN1 reverse  5'-CAGCCCAACTGTAAACACCA-3', CTGF forward 5′-CTGCCAGTG 
GAGTTCAAATGC-3′ and CTGF reverse 5′-TCATTGTCCCCAGGACAGTTG-3′, collagen-1 
forward 5′-TGTGTTCCCTACTCAGCCGTCT-3′ and collagen-1 reverse 5′-CATCGGTCATGC 
TCTCTCCAA-3′, PDGF-B forward 5′-CCCACAGTGGCTTTTCATTT-3′ and PDGF-B reverse 
5′-GTGGAGGAGCAGACTGAAGG-3′, VEGF forward 5'-CGCGAGTCTGTGTTTTTGCA-3′ 
and VEGF reverse 5'-CAGAGCGGAGAAAGCATTTGT-3', TGF forward 5'-
CAATACGTCAGACATTCGGGAAGC-3' and TGF reverse 5'- 
CTGGTAGAGTTCTACGTGTTGCTC-3', and RPL19 forward 5′ 
ATGCCAACTCCCGTCAGCAG-3′ and RPL19 reverse 5′-
TCATCCTTCTCATCCAGGTCACC-3'. Expression values of XBP1s were normalized to that of 
XBP1us using the 2ΔCt method. Expression values of all other genes were normalized to RPL19 
also using the 2ΔCt method. Evaluation of XBP1 splicing by separation of spliced and unspliced 
cDNA products on an agarose gel was performed as previously described. For cDNA synthesis for 
this evaluation, the following primers were used: XBP1 forward 5′-
CTGGAAAGCAAGTGGTAGA-3′ and XBP1 reverse 5′-CTGGGTCCTTCTGGGTAGAC-3′. 
Mouse apoptosis PCR array 
 The Mouse Apoptosis RT2 Profiler PCR Array (Qiagen) was used. MLE12 cells were 
plated at 40%–50% confluence in 6-well plates in antibiotic-free DMEM media. Twenty-four 
hours later, MLE12 cells were transfected with Smartpool siRNA for CHOP or control nontargeted 
siRNA. Following transfection, cells were exposed to hypoxia (1.5% O2) or normoxia (21% O2) 
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for an additional 48 hours. After mRNA isolation, cDNA was synthesized using the RT2 First 
Strand Kit (Qiagen) and qPCR was performed using RT2 qPCR master mixes (Qiagen). 
Isolation of EpCAM+ cells 
Lungs were enzymatically digested using Dispase II (MilliporeSigma) for 45 minutes at 
37°C and passed through 100-μM and 40-μM SwiftStrain Cell Strainers (Denville), followed by 
the 20-μM Steriflip vacuum filter (EMD Millipore) to obtain single-cell suspensions. The single-
cell suspension was then coated with mouse CD45 microbeads as per the manufacturer’s 
instructions (Macs Miltenyi Biotech). CD45+ cells were depleted by passing the CD45-coated 
single-cell suspension through LD columns on a QuadroMACS Separator (Macs Miltenyi Biotech) 
as per the manufacturer’s instructions. The flow through containing CD45– cells was then coated 
with mouse EpCAM microbeads as per the manufacturer’s instructions (Macs Miltenyi Biotech). 
EpCAM+ cells were collected by passing EpCAM-coated single-cell suspension through LS 
columns on a QuadroMACS Separator as per the manufacturer’s instructions. 
RNA-sequencing 
 Total RNA was isolated from EpCAM+ cells using Direct-Zol RNA MiniPrep (Zymo 
Research), followed by DNA Digestion (Ambion, Invitrogen). The quality check of the RNA, 
mRNA enrichment, and cDNA library preparation utilizing stranded mRNA (polyA selected) were 
conducted at Vanderbilt Technologies for Advanced Genomics. RNA sequencing was performed 
on an Illumina NovaSeq6000 system with a paired-end mRNA library prep, PE-150, with 30 
million reads. Initial alignment and quantification were performed using the Partek Flow package. 
STAR 2.5.3a was used to align RNA-sequencing reads, with quantification performed by Ensembl 
Transcripts Release 83 using Partek E/M. Reads were normalized to total count. Differentially 
expressed genes were determined based on >2-fold change (log2 ratio > 1) between groups, with 
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P < 0.05 and FDR < 0.05. Annotation of overrepresented pathways was done using WebGestalt 
(WEB-based Gene SeT AnaLysis Toolkit). 
Statistics 
Statistical analyses were performed using GraphPad Prism Software. Data are presented as 
mean ± SEM. Survival data were assessed using a Kaplan-Meier survival analysis. Pairwise 
comparisons were made using 2-tailed, unpaired Student’s t test. Comparisons between groups 
were made by 1-way ANOVA, followed by Tukey’s post hoc test. P values of less than 0.05 were 
considered significant. 
Study approval 
 Tissue collection and studies were approved by the Vanderbilt University Institutional 
Review Board (060165). All experimental protocols were approved by the Animal Care and 
Utilization Institutional Committee at Vanderbilt University Medical Center. 
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III. HYPOXIA WORSENS LUNG FIBROSIS THROUGH EXPRESSION 
OF ER STRESS EFFECTOR C/EBP HOMOLOGOUS PROTEIN 
(CHOP) 
 
CHOP regulates epithelial cell survival and mediates lung fibrosis in the 
presence of ER stress 
We investigated the mechanisms by which ER stress contributes to pulmonary fibrosis 
using a repetitive intratracheal (i.t.) bleomycin injury model; we have previously demonstrated 
that this model recapitulates important features of human IPF, including hyperplastic AECs and 
persistent fibrosis (135). In this model, we treated 8 to 10 week old male and female WT mice 
(C57BL/6J background) with 6 doses of bleomycin (0.04 units) delivered by direct i.t. instillation 
at 2-week intervals. Mice were euthanized and lungs were harvested 2 weeks after the final 
bleomycin instillation. Consistent with previous findings (135), we observed distinct areas of 
parenchymal fibrosis with type II AEC hyperplasia (Figure 9A). Markers of ER stress were 
markedly upregulated, as shown by western blotting of lung lysates, including CHOP, protein 
disulphide isomerase (PDI), activating transcription factor 4 (ATF4), and spliced X-box binding 
protein 1 (XBP1s) (Figure 9B). By IHC, we found that CHOP expression was localized primarily 
to type II AECs in areas of fibrosis (Figure 9C).   
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Next, we performed experiments using repetitive i.t. bleomycin in CHOP-deficient 
(CHOP–/–) mice to determine whether CHOP is an important profibrotic mediator in this model 
(Figure 10, A–E). In these studies, we observed significant protection of CHOP–/– mice from 
development of lung fibrosis, with a marked reduction in fibrotic area, reduced soluble collagen 
content, and decreased fibronectin level by ELISA (Figure 10, A–D). Since AEC apoptosis is an 
important antecedent of bleomycin-induced fibrosis, we quantified apoptotic AECs by 
colocalization of pro-SPC and TUNEL staining. We found that the number of TUNEL+ AECs 
was significantly lower in repetitive bleomycin-treated CHOP–/– mice compared with WT controls 
(Figure 10E). Together, these studies suggest that CHOP deficiency protects from lung fibrosis 
following repetitive bleomycin by reducing AEC apoptosis. To more directly test the role of CHOP 
in AECs, we investigated whether selective induction of ER stress in type II AECs affects lung 
fibrosis via CHOP induction. For these studies, we utilized a doxycycline-inducible transgenic 
model in which expression of a mutant form of human SFTPC (L188Q SFTPC) is limited to type 
II AECs (99), resulting in ER stress and enhanced fibrotic susceptibility (99). After crossing 
CHOP–/– mice into this model to generate L188Q SFTPC/CHOP–/– mice, we treated these mice 
with doxycycline in drinking water (2 g/l) for 1 week and then administered a single i.t. injection 
Figure 9. Repetitive bleomycin treatment results in ER stress and lung fibrosis. (A) 
Representative Masson’s trichrome stained lung sections and immunostaining for pro-
surfactant protein C (pro-SPC) showing areas of fibrosis and hyperplastic type II alveolar 
epithelial cells (AECs) following intratracheal (IT) injection of bleomycin (0.04 units) every 2 
weeks for 6 doses (Rep Bleo) compared to untreated controls. Scale bars - low mag: 800 µm, 
high mag: 60 µm. (B) Western blots and densitometry for CHOP, PDI, ATF4, and XBP1s from 
lung tissue lysates (left panel) and densitometry (right panel). β-actin was used as a loading 
control. Comparisons between groups were made using unpaired, two-tailed Student’s t-test. 
*=p<0.05 compared to untreated WT.  (C) Representative immunostaining for CHOP (arrows 
indicate CHOP staining) and quantification of CHOP positive AECs per high power field (HPF) 
on lung sections.  *=p<0.05 compared to other groups by one way ANOVA with Tukey’s post-
hoc test. 
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of bleomycin (0.08 units). At 3 weeks after bleomycin instillation, L188Q SFTPC mice had 
increased lung fibrosis compared with WT controls, but CHOP deficiency (L188Q SFTPC/CHOP–
/– mice) reduced fibrosis to WT levels (Figure 10, F and G). Notably, no difference in fibrosis 
was observed between WT and CHOP–/– mice used as controls in these experiments. Single-dose 
i.t. bleomycin did not induce robust CHOP upregulation in WT mice, potentially explaining why 
CHOP deletion was not protective in this model (Figure 10 and 11). Collectively, these studies in 
two different fibrosis models indicate that CHOP is a key mediator of lung fibrosis when expressed 
in AECs. 
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CHOP regulates epithelial cell responses and inflammation following 
repetitive bleomycin treatment 
To evaluate the effect of CHOP on potential profibrotic pathways, we analyzed gene 
expression by RNA sequencing of EpCAM+ (EpCAM is also known as CD326) cells isolated 
from lungs of WT and CHOP–/– mice following repetitive bleomycin treatment (Figure 12). 
Compared with that in lung epithelial cells from untreated WT mice, 2,156 genes were 
Figure 10. CHOP mediates the effects of ER stress on epithelial cell apoptosis and lung 
fibrosis. (A-E) WT and CHOP-/- mice were studied using the repetitive bleomycin model (Rep 
Bleo) and lungs were harvested 2 weeks after the last dose. (A) Representative Masson’s 
trichrome stained lung sections. Scale bars: 800 µm. (B) Evaluation of fibrosis by 
morphometry.  (C) Quantification of total soluble collagen in right lower lobe (RLL) by sircol 
assay. (D) Fibronectin measurement by ELISA. (E) Quantification of dual 
immunofluorescence for pro-SPC positive and TUNEL positive cells per high power field 
(HPF) on lung sections. Comparisons between groups were made using unpaired, two-tailed 
Student’s t-test (B and D) or one way ANOVA with Tukey’s post-hoc test (C and E). *=p<0.05 
compared to WT + rep bleo, **=p<0.05 compared to untreated WT. (F-H) Inducible transgenic 
mice expressing L188Q mutant surfactant protein C (L188Q SFTPC), CHOP-/- mice, L188Q 
SFTPC/CHOP-/- mice, and WT mice were treated with doxycycline (2 g/l) for 1 week followed 
by intratracheal injection of bleomycin (0.08 units) and lungs were harvested 3 weeks post-
bleomycin. (F)  Morphometric evaluation of fibrosis. (G) Total soluble collagen in right lower 
lobe (RLL) by sircol assay. (H) Densitometry on western blot for CHOP from lung tissue 
lysates. β-actin was used for normalization. *=p<0.05 compared to other groups by one way 
ANOVA with Tukey’s post-hoc test (F-H). 
Figure 11. CHOP levels in inducible transgenic mice expressing L188Q surfactant protein 
C (L188Q SFTPC) treated with bleomycin compared to wild type mice.  L188Q SFTPC 
and WT controls were treated with doxycycline (2 g/l) for 1 week followed by intratracheal 
injection of bleomycin (0.08 units) and lungs were harvested 3 weeks later. Untreated WT mice 
were used as an additional control. Western blot for CHOP from lung tissue lysates is shown 
along with β-actin as loading control.  
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differentially expressed (fold change > 2, P < 0.05, FDR < 0.05), including some ER stress genes, 
in repetitive bleomycin-treated WT mice (Figure 12, A and B). From among this set of 
differentially expressed genes, 127 genes were differentially expressed in epithelial cells from WT 
and CHOP–/– mice following repetitive bleomycin (Figure 12A). By gene ontology analysis, 46 
of these gene products were grouped into the following 4 categories: (a) cellular response to growth 
factor stimulus, (b) epithelial cell differentiation, (c) epithelium development, and (d) cell 
migration (Figure 12C), thereby suggesting several profibrotic pathways in the epithelial 
compartment that could be regulated by CHOP. We also investigated whether CHOP regulates 
inflammatory cell recruitment or function. We compared the inflammatory response in CHOP–/– 
mice with that of WT controls following repetitive bleomycin treatment. As shown in Figure 13, 
significant differences were not detected in numbers of immune/inflammatory cells in the lungs of 
WT and CHOP–/– mice (alveolar macrophages, interstitial macrophages,  B or T lymphocytes), 
with the exception of neutrophils and dendritic cells, which were reduced in the lungs of CHOP–/– 
mice. 
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Figure 12. Gene expression profiling of EpCAM positive epithelial cells isolated from 
wild type and CHOP deficient mice in the repetitive bleomycin model. WT and CHOP-
/- mice were intratracheally injected with 6 doses of bleomycin (0.04 units) at intervals of 2 
weeks and lungs were harvested 2 weeks after the last dose. EpCAM positive epithelial 
cells were isolated from the lungs of bleomycin-treated (Rep Bleo) mice and control 
(untreated) WT mice. Total RNA was extracted from the isolated EpCAM positive cells 
and used for RNA-sequencing. n=3-4 mice in each group. (A) Pie-charts showing 
differentially regulated genes (fold change>2, p value<0.05, and FDR<0.05) between 
groups. The subset of genes differentially regulated between the WT + Rep Bleo group and 
WT Untreated group was examined in epithelial cells from the CHOP-/- + Rep Bleo group. 
(B) Plots showing expression of representative ER stress genes. Comparisons between 
groups were made using unpaired, two-tailed Student’s t-test. *p<0.05 compared to WT 
Untreated. (C) Differentially regulated GO pathways in CHOP-/- + Rep Bleo compared to 
WT + Rep Bleo. 
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Repetitive bleomycin injury results in localized tissue hypoxia 
Although a variety of factors can affect protein processing in the ER, the mechanism by 
which repetitive lung injury causes ER stress is unknown. Since hypoxia has been shown to cause 
ER stress in vitro (143), we postulated that localized areas of hypoxia in lung parenchyma could 
induce ER stress during repetitive cycles of lung injury and repair. To evaluate this possibility, we 
utilized pimonidazole as a chemical marker of cellular hypoxia (144) delivered by i.p. injection 
(60 μg/g) 3 hours prior to euthanasia in the repetitive bleomycin model. We then harvested lungs 
and performed IHC for pimonidazole adducts. Strong immunostaining was observed in areas of 
fibrosis, while minimal pimonidazole staining was identified in lungs of control (non bleomycin-
treated) mice and in nonfibrotic areas of lungs of mice treated with repetitive bleomycin (Figure 
14A). Using dual immunofluorescence for pimonidazole adducts and the type II AEC marker pro-
SPC, we found that pimonidazole staining colocalized in this cell population. Quantification of 
dual immunofluorescence revealed that 65.3% ± 1.2% of pro-SPC+ cells were also positive for 
pimonidazole staining in areas of fibrosis, whereas almost none of the pro-SPC+ cells in control 
(non bleomycin-treated) mice stained for pimonidazole (Figure 14, B and C).  
Figure 13. Immune/inflammatory cells identified in lungs of wild type and CHOP 
deficient mice following repetitive bleomycin treatment.  Mice were intratracheally injected 
with 6 doses of bleomycin (0.04 units) at intervals of 2 weeks and lungs were harvested 2 weeks 
after the last dose for flow cytometry analysis. (A-B) Gating strategy and quantification of 
myeloid cell subsets obtained from single cell suspensions of lung tissue. Viable (DAPI-) 
CD45+ cells were gated and percentages of alveolar macrophages (CD103-CD11c+), 
interstitial macrophages (CD103-CD11c-CD11b+Ly6G-), dendritic cells (CD103+CD11c+), 
and neutrophils (CD103-CD11c-Ly6G+CD11b+) were determined. (C-D) Gating strategy and 
quantitation of lymphocytes. Viable (DAPI-) CD45+ cells were gated and percentages of B 
cells (CD19+) and T cells (CD3+) were determined.  Comparison between groups was made 
using unpaired, two-tailed Student’s t-test. *=p<0.05 compared to WT. 
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We also performed dual immunofluorescence for pimonidazole adducts and markers of 
type I AECs, fibroblasts, endothelial cells, and macrophages and found minimal colocalization in 
all of these cell types (Figure 15). Based on these data, we concluded that repetitive bleomycin 
injury results in localized hypoxia in lung parenchyma that is primarily detectable in type II AECs. 
Figure 14. Repetitive bleomycin treatment results in cellular hypoxia localized to type II 
AECs. (A) Intraperitoneal injection of pimonidazole (60 μg/g) was performed 3 hours before 
euthanasia in mice treated with repetitive intratracheal bleomycin, followed by immunostaining 
for pimonidazole adducts on lung sections. Scale bars - low mag: 800 µm, high mag: 80 µm. 
(B) Dual immunofluorescence for pimonidazole adducts (red) and pro-SPC for type II AECs 
(green). Nuclei were counterstained with DAPI (blue). White arrows point to cells with co-
localization (yellow). Scale bar: 80 µm. (C) Quantification of the percentage of pro-SPC 
positive cells which were also positive for pimonidazole per high power field (HPF). 
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Figure 15. Dual immunofluorescence between pimonidazole and markers of type I AECs, 
fibroblasts, endothelial cells, or macrophages in the repetitive dose bleomycin model. (A-
D) Dual immunofluorescence for pimonidazole (red) and markers for type I AECs (T1α), 
fibroblasts (S100A4), endothelial cells (CD34), or macrophages (F4/80) (all green) was 
performed on lung sections of mice treated in the repetitive bleomycin model. Nuclei were 
counterstained with DAPI (blue).   
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Exposure to hypoxia following bleomycin injury increases ER stress and 
worsens lung fibrosis 
Since our studies suggested that cellular hypoxia could cause ER stress and promote CHOP 
expression in type II AECs, we sought to develop a model to test this idea. We reasoned that 
exposure of bleomycin-treated mice to normobaric hypoxia could exacerbate local hypoxia in the 
lungs and worsen fibrosis. Therefore, we treated mice with a single dose of i.t. bleomycin (0.04 
units) and then exposed mice to hypoxia from day 7 to day 21 after bleomycin (Figure 16). As 
shown in Figure 16B, 10% O2 was uniformly lethal and 12% O2 resulted in 50% mortality by 
day 21; however, 14% O2 was relatively well tolerated (10% mortality). To determine whether 
exposure to 14% O2 was sufficient to exacerbate cellular hypoxia in the lungs, we injected 
pimonidazole and performed IHC on lung sections obtained at day 21 after bleomycin treatment 
(14 days of hypoxia). While no pimonidazole staining was observed in unchallenged mice exposed 
to 14% O2 and minimal staining was detected in bleomycin-challenged mice maintained in 
normoxia, there was robust pimonidazole staining in areas of bleomycin-induced fibrosis in mice 
exposed to 14% O2 (Figure 16C). As in the repetitive bleomycin model, pimonidazole staining 
strongly colocalized with pro-SPC+ type II AECs (Figure 17, A and B), while S100A4+ 
fibroblasts, T1α+ type I AECs, CD34+ endothelial cells, and F4/80+ macrophages did not have 
detectable colocalization with pimonidazole adducts (Figure 17, C–F). With evidence that 
exposure to 14% O2 following bleomycin injury was associated with cellular hypoxia in AECs, 
we evaluated ER stress markers and found that CHOP, PDI, ATF4, and XBP1s were upregulated 
in lung tissue from mice treated with bleomycin followed by 14% O2 (Figure 16D). By 
quantification of IHC, we found a marked induction of CHOP in AECs in lungs of mice treated 
with bleomycin followed by 14% O2 (Figure 16, C and E).  
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Consistent with our findings in other fibrosis models characterized by robust induction of ER 
stress, mice treated with bleomycin followed by 14% O2 had a marked exacerbation of fibrosis 
compared with bleomycin-treated mice maintained in normoxia (Figure 16, F–H). 
 
 
 
 
 
 
 
 
 
 
Figure 16. Exposure to hypoxia following bleomycin treatment increases ER stress and 
worsens lung fibrosis. (A) Schematic representation of experimental design in which a single 
dose of bleomycin (0.04 units) was injected intratracheally followed 7 days later by exposure 
to normobaric hypoxia or normoxia (21% O2) for an additional 14 days. (B) Kaplan-Meier 
survival plot for mice treated with bleomycin and exposed to 21%, 14%, 12%, or 10% O2. n = 
48 (in 21% O2), 35 (in 14% O2), 16 (in 12% O2), and 12 (in 10% O2). (C) Representative 
immunostaining for CHOP expression and pimonidazole adducts in mice injected with 
pimonidazole (60 μg/g) at 3 hours before lung harvest. Mice were treated with bleomycin 
followed 7 days later by exposure to 14% O2 for an additional 14 days or maintained in 21% 
O2. Additional controls were only exposed to 14% O2 for 2 weeks or were maintained in 21% 
O2. Scale bars - low mag: 800 µm, high mag: 60 µm. (D) Western blots for ER stress markers 
CHOP, PDI, ATF4, and XBP1s in lung tissue lysates. β-actin was used as a loading control. 
(E) Quantification of CHOP positive AECs per high power field (HPF) on lung sections. (F) 
Masson’s trichrome staining and (G) Morphometric evaluation of lung fibrosis. (H) Total 
soluble collagen in right lower lobe (RLL) by sircol assay. Comparisons between groups were 
made using unpaired, two-tailed Student’s t-test (G) or one way ANOVA with Tukey’s post-
hoc test (E and H). *=p<0.05 compared to single bleo + 21% O2, **=p<0.05 compared to 
untreated + 21% O2. 
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CHOP–/– mice are protected from exaggerated lung fibrosis induced by 
exposure to hypoxia 
To test whether CHOP mediates the excess lung fibrosis resulting from exposure to 
hypoxia following bleomycin treatment, we treated WT and CHOP–/– mice with a single i.t. injection 
of bleomycin (0.04 units) followed by randomization to normoxia (21% O2) or hypoxia (14% O2) 
between day 7 and day 21 after bleomycin. As shown in Figure 18, A–C, the hypoxia-induced 
exacerbation of lung fibrosis was completely abrogated in CHOP–/– mice. CHOP deficiency had 
no detectable effects in mice treated with single-dose bleomycin and maintained in normoxia. 
Since AEC apoptosis following single-dose bleomycin is most prominent within the first 2 weeks 
after treatment (145), we tested whether exposure of bleomycin-treated mice to 14% O2 for 3 
days (between day 7–10 after bleomycin) exacerbates AEC apoptosis and if this effect is 
mediated by CHOP. In lungs harvested at 10 days after bleomycin, quantification of pro-SPC and 
TUNEL dual-positive cells showed that AEC apoptosis was increased in WT mice exposed to 
hypoxia compared with WT mice maintained in normoxia and that this increase was mitigated in 
lungs of CHOP–/– mice (Figure 18D). 
 
 
Figure 17. Dual immunofluorescence between pimonidazole and markers of different cell 
types in lungs of mice treated with bleomycin followed by exposure to hypoxia (14% O2). 
Dual immunofluorescence (IF) for pimonidazole (red) and cell specific markers (green) was 
performed in lungs of mice treated with intratracheal bleomycin (0.04 units) followed 7 days 
later by exposure to 14% O2 for an additional 14 days or maintained in 21% O2.  Additional 
controls were only exposed to 14% O2 for 2 weeks or were maintained in 21% O2. (A) Dual IF 
is shown for type II AECs (pro-SPC). Nuclei were counterstained with DAPI (blue). White 
arrows point to cells with co-localization (yellow) of pimonidazole (red) and pro-SPC (green). 
(B) Quantification of the percentage of pro-SPC positive cells which were also positive for 
pimonidazole per high power field (HPF).  Comparison between groups was made using 
unpaired, two-tailed Student’s t-test. *=p<0.05 compared to single bleo + 21% O2. Dual IF is 
also shown for (C) type I AECs (T1α), (D) endothelial cells (CD34), (E) macrophages (F4/80), 
and (F) fibroblasts (S100A4). Nuclei were counterstained with DAPI (blue).  
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Figure 18. CHOP deficient mice are protected from exaggerated lung fibrosis induced by 
exposure to hypoxia. (A-D) WT and CHOP-/- mice received an intratracheal injection 
of bleomycin (0.04 units) followed 7 days later by exposure to 14% O2 or 21% O2. (A) 
Representative Masson’s trichrome staining (Scale bars: 800 µm) and (B) Morphometric 
evaluation of lung fibrosis at 21 days after bleomycin injection. (C) Total soluble collagen in 
right lower lobe (RLL) by sircol assay. (D)  Quantification of dual immunofluorescence for 
pro-SPC positive and TUNEL positive cells per high power field (HPF) on sections from lungs 
harvested 3 days after randomization to 21% O2 or 14% O2 (10 days after bleomycin injection). 
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We also examined whether CHOP–/– mice had differences in lung immune/inflammatory 
cell populations in the bleomycin followed by hypoxia model. At 21 days after bleomycin 
treatment, we found no differences in myeloid cell subsets (Figure 19A) or lymphocytes (Figure 
19B) between CHOP–/– and WT mice exposed to 14% O2 or maintained in normoxia. Since M2 
macrophage polarization has been associated with lung fibrosis (146-148), we also isolated lung 
macrophages and examined whether CHOP deficiency alters macrophage polarization; however, 
no M1/M2 phenotype shift was observed in CHOP–/– mice following bleomycin treatment in either 
the normoxia or hypoxia groups (Figure 19C).  
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Since bleomycin results in inflammation that peaks between 1 and 2 weeks after exposure, 
we also evaluated inflammation during this time period at 10 days after bleomycin injection 
(exposure to 21% O2 or 14% O2 for 3 days between 7 and 10 days after bleomycin). Similar to 
our findings at day 21 after bleomycin, numbers of lymphocytes were similar in the lungs of WT 
and CHOP–/– mice in normoxia and hypoxia. In contrast, neutrophils and interstitial macrophages 
were reduced in bleomycin-treated CHOP–/– mice compared with WT mice in hypoxia, while 
numbers of alveolar macrophages and dendritic cells were similar (Figure 20, A and B). 
Regarding macrophage polarization, no difference in the pattern of M1/ M2 markers was observed 
between WT and CHOP–/– mice following bleomycin treatment in normoxia or hypoxia (Figure 
20C). 
 
 
 
Figure 19. WT and CHOP-/- mice were treated with intratracheal bleomycin (0.04 units) 
followed 7 days later by exposure to 14% O2 for an additional 14 days or maintained in 
21% O2. Lungs were harvested at 21 days post-bleomycin and immune/inflammatory 
cells were analyzed by flow cytometry. (A) Percentage of viable CD45+ cells in the lungs 
identified as alveolar macrophages (CD103-CD11c+), interstitial macrophages (CD103-
CD11c-CD11b+Ly6G-), dendritic cells (CD103+CD11c+), or neutrophils (CD103-CD11c-
Ly6G+CD11b+). (B) Percentage of viable CD45+ cells in the lungs identified as B cells 
(CD19+) and T cells (CD3+). (C) WT and CHOP-/- mice were treated with intratracheal 
bleomycin (0.04 units) followed 7 days later by exposure to 14% O2 for an additional 14 days 
or maintained in 21% O2. Lungs were harvested at 21 days post-bleomycin and macrophages 
were isolated from single cell suspensions by adherence to plastic and mRNA was isolated for 
qPCR quantification of M1 macrophage markers (IL-6, TNFα, iNOS, and IL-12) and M2 
macrophage markers (Arginase, IL-10, Ym1, Mannose Receptor). GAPDH was used for 
normalization. Comparisons between groups were made using one way ANOVA with Tukey’s 
post-hoc test. *=p<0.05 compared to WT +14% O2. 
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Consistent with similar macrophage polarization among treatment groups, no evidence of CHOP 
induction was observed in macrophages isolated from bleomycin-treated WT mice in either 
hypoxia or normoxia (Figure 21) 
 
 
 
Figure 20. Immune/inflammatory cells and M1/M2 markers in macrophages from lungs of 
wild type and CHOP deficient mice following single dose IT bleomycin treatment with or 
without subsequent exposure to hypoxia (14% O2) and harvested at day 10 post-
bleomycin. WT and CHOP-/- mice were treated with intratracheal bleomycin (0.04 units) 
followed 7 days later by exposure to 14% O2 for an additional 3 days or maintained in 21% O2. 
Lungs were harvested at 10 days post-bleomycin and immune/inflammatory cells were analyzed 
by flow cytometry. (A) Percentage of viable CD45+ cells in the lungs identified as alveolar 
macrophages (CD103-CD11c+), interstitial macrophages (CD103-CD11c-CD11b+Ly6G-), 
dendritic cells (CD103+CD11c+), or neutrophils (CD103-CD11c-Ly6G+CD11b+). (B) 
Percentage of viable CD45+ cells in the lungs identified as B cells (CD19+) and T cells (CD3+). 
(C) WT and CHOP-/- mice were treated with intratracheal bleomycin (0.04 units) followed 7 
days later by exposure to 14% O2 for an additional 3 days or maintained in 21% O2. Lungs were 
harvested at 10 days post-bleomycin and macrophages were isolated from single cell suspensions 
by adherence to plastic. mRNA was isolated for qPCR quantification of M1 macrophage markers 
(IL-6, TNFα, iNOS, and IL-12) and M2 macrophage markers (Arginase, IL-10, Ym1, Mannose 
Receptor). GAPDH was used for normalization.  Comparisons between groups were made using 
one way ANOVA with Tukey’s post-hoc test. *=p<0.05 compared to WT + 14% O2. 
Figure 21. CHOP expression in 
macrophages isolated from mice 
in the bleomycin followed by 
hypoxia model. WT and CHOP-/- 
mice were treated with intratracheal 
bleomycin (0.04 units) followed 7 
days later by exposure to 14% O2 for 
an additional 14 days (A) or 3 days 
(B). Control mice were maintained 
in 21% O2. Lungs were harvested 
and macrophages were isolated from 
single cell suspensions by adherence 
in tissue culture plates. mRNA was 
isolated for qPCR quantification of 
CHOP and GAPDH was used for 
normalization.  Comparisons 
between groups were made using 
one way ANOVA with Tukey’s 
post-hoc test. NS= non-significant.  
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CHOP and markers of hypoxia are prominently expressed in lungs of IPF 
patients 
We evaluated the expression of CHOP and hypoxia markers in lungs of IPF patients and 
non-IPF controls. We observed induction of CHOP in IPF lungs by IHC on lung sections and by 
Western blotting of lung tissue homogenates. CHOP was predominantly expressed in hyperplastic 
type II AECs in areas of fibrosis. Additionally, we observed prominent expression of hypoxia 
markers HIF1α, pyruvate kinase, and carbonic anhydrase IX in hyperplastic type II AECs in IPF 
lungs, with a pattern similar to CHOP staining (Figure 22). Together, these studies in lung 
specimens from IPF patients provide further evidence for a connection between localized hypoxia 
and ER stress in this disease. 
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Figure 22. CHOP and markers of hypoxia are prominently expressed in lungs of IPF 
patients. (A) Representative immunostaining for CHOP, HIF1α, pyruvate kinase, and carbonic 
anhydrase IX (CA-IX) on lung sections of IPF patients and non-IPF control lungs. Arrows 
indicate positive staining in type II AECs. Scale bars: 60 µm. (B) Western blot (left panel) and 
densitometry (right panel) for CHOP on protein from lung tissue lysates of IPF patients and 
non-IPF controls. β-actin was used as a loading control.  Comparisons between groups were 
made using unpaired two-tailed Student’s t-test. *=p<0.05.  
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DISCUSSION 
 
Our studies indicate that localized hypoxia augments ER stress and induces CHOP 
expression in AECs, thus favoring fibrotic remodeling over effective repair. These studies point to 
a distinction between the standard injury-repair model (single-dose i.t. bleomycin) and models 
involving sequential or repetitive injuries that worsen or prolong fibrotic remodeling. CHOP was 
not required for fibrosis in the single-dose bleomycin model, where CHOP induction was minimal. 
In contrast, CHOP was shown to be a critical mediator of fibrosis in models with substantial ER 
stress, including repetitive-dose bleomycin, bleomycin treatment in mice with L188Q SFTPC-
induced ER stress in AECs, and bleomycin followed by hypoxia, thereby suggesting that CHOP 
(and ER stress) may be more important in progression, rather than initiation, of fibrosis.  
CHOP expression has been linked to a number of ER stress–mediated pathologies in the 
kidneys, pancreas, heart, and liver, including diseases with progressive remodeling and organ 
dysfunction (20, 21, 149, 150). In lung fibrosis, prior studies regarding the role of CHOP have 
yielded conflicting results, with two reports showing that CHOP–/– mice have reduced fibrosis after 
single-dose i.t. bleomycin treatment (96, 100) and another report showing markedly worse survival 
and increased fibrosis in CHOP–/– mice after single-dose i.t. bleomycin treatment (101). The latter 
study also found that mice with heterozygous deletion of binding immunoglobulin protein (BiP), 
which should exacerbate ER stress through reduced chaperone function, were protected from lung 
fibrosis through increased CHOP-dependent macrophage apoptosis. In contrast to these studies, 
we found no effects of CHOP deficiency in the standard single-dose bleomycin model using two 
different doses of bleomycin (0.04 units and 0.08 units). Although the explanation for the 
discrepancy between these studies is not obvious, our findings suggest that CHOP regulation of 
fibrosis differs depending on the ER stress–dependent contribution to the fibrotic phenotype. 
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Specifically, CHOP deficiency in bleomycin-treated L188Q SFTPC/CHOP–/– mice reduced 
fibrosis only to the level observed in bleomycin-treated WT mice, and similarly, CHOP–/– mice 
exposed to hypoxia following single-dose bleomycin developed lung fibrosis equivalent to that of 
WT mice treated with single-dose bleomycin and maintained in normoxia. 
CHOP is a transcription factor that plays an important role in regulating ER stress–induced 
apoptosis (151). Our studies implicate CHOP-induced AEC apoptosis as an important mechanism 
inﬂuencing fibrosis severity. Several studies have implicated CHOP in regulating inflammatory 
signaling (152). In this regard, CHOP was reported to regulate M2 macrophage polarization in 
lung fibrosis induced by single-dose bleomycin (96); however, in our studies, we did not observe 
induction of CHOP in macrophages and CHOP deficiency did not affect macrophage polarization 
in any of our models. CHOP deficiency did reduce the number of neutrophils in the lungs following 
repetitive-bleomycin treatment and at day 10 in the bleomycin followed by hypoxia model 
(interstitial macrophages were reduced at day 10 in this model as well). It is unclear whether these 
changes in inflammatory cells effect fibrosis in these models; we speculate that the observed 
decrease in these inflammatory cell subtypes may be secondary to reduced epithelial injury and 
death, rather than a direct effect of CHOP in inflammatory cells. In addition to epithelial cell 
survival and regulation of inflammation, our epithelial cell expression profiling studies suggested 
that CHOP may affect a number of other cellular phenotypes that could affect fibrotic remodeling, 
including epithelial differentiation, growth factor responses, and cell migration. 
 Our finding of localized hypoxia in the repetitive bleomycin model is an important advance 
in understanding how ER stress could be generated in IPF. In our studies, we identified 
pimonidazole adducts, which require a very low pO2 (≤10 mmHg) for generation, as a marker of 
cellular hypoxia in type II AECs in the repetitive bleomycin treatment model and the single-dose 
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bleomycin followed by hypoxia model. Depletion of oxygen to the level required for pimonidazole 
adduct formation may occur preferentially in AECs because of the high metabolic activity of these 
cells (145). Our model of exposure to 14% O2, which is equivalent to ascension to an altitude of 
approximately 10,500 feet above sea level, after bleomycin injury makes it possible for future 
studies to further investigate the specific contribution of hypoxia to development of lung fibrosis. 
 In summary, these data (a) provide evidence that the UPR-downstream effector CHOP 
plays a critical role in mediating the effects of ER stress in lung fibrosis, likely through increasing 
apoptosis of AECs and impairing re-epithelialization and restoration of lung architecture, and (b) 
suggest localized hypoxia in the injured/damaged lung parenchyma to be a potential explanation 
for ER stress, almost universally observed in lungs of IPF patients.  
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IV. REGULATION AND DOWNSTREAM FUNCTION OF C/EBP 
HOMOLOGOUS PROTEIN (CHOP) IN ALVEOLAR EPITHELIAL 
CELLS IN HYPOXIA 
 
Hypoxia induces CHOP expression in AECs through the IRE1α/XBP1 and 
PERK/ATF4 pathways 
 To investigate the regulation of CHOP expression by hypoxia, we exposed a type II AEC 
line (MLE12 cells) to hypoxia (1.5% O2 ) for 24–48 hours. By Western blotting and qPCR, we 
found upregulation of CHOP in hypoxic cells compared with cells cultured in room air (21% O2 
) (Figure 23A). In addition, we found increased expression of ATF4 (a measure of activation of 
PKR-like ER kinase [PERK]) and spliced XBP1 (a measure of activation of inositol-requiring 
enzyme 1 [IRE1]) following hypoxia exposure. In contrast, cleaved activating transcription factor 
6 (ATF6) and IRE1α levels remained unchanged after exposure to hypoxia (Figure 23, B and C). 
To determine the regulation of CHOP expression in hypoxia, we used small-molecule inhibitors 
to disrupt IRE1α or PERK activity in MLE12 cells. We treated MLE12 cells with a small-molecule 
inhibitor of IRE1α (PCP-101, Mannkind Corporation), which interacts directly with the RNase 
active site of IRE1α and blocks XBP1 mRNA splicing (153-155), or DMSO as vehicle control. 
Following treatment, cells were exposed to 1.5% O2 or room air for 48 hours. Treatment of MLE12 
cells with PCP-101 efficiently blocked XBP1 splicing and markedly reduced CHOP induction in 
hypoxia, without affecting ATF4 induction (Figure 23, D and E). These data show an important 
role of the IRE1α/XBP1 pathway in hypoxia-induced CHOP expression. In confirmation of this 
finding, treatment of MLE12 cells with an IRE1 siRNA also prevented CHOP induction in hypoxia 
(Figure 24). Next, to evaluate the role of the PERK/ATF4 pathway, we treated MLE12 cells with 
a small-molecule inhibitor of PERK (GSK2606414) or DMSO as vehicle control, followed by 
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exposure to hypoxia for 48 hours. PERK inhibition led to a reduction in ATF4 expression and a 
concomitant decrease in CHOP expression, without affecting XBP1 splicing (Figure 23F). 
siRNA-mediated inhibition of ATF4 signaling led to a slight reduction in CHOP levels in hypoxia 
(Figure 24). Taken together, these data suggest that both the IRE1/XBP1s and the PERK/ATF4 
arms of the UPR pathways contribute to CHOP induction in hypoxia. To evaluate the role of HIF 
signaling in regulating CHOP expression in AECs, we treated MLE12 cells with siRNA directed 
toward HIF1α, followed by exposure to hypoxia (1.5% O2). While we observed efficient HIF1α 
knockdown (Figure 25), hypoxia-induced CHOP expression was unchanged (Figure 23G), 
suggesting that HIF and CHOP are independently regulated. 
 
64 
 
65 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Hypoxia induces CHOP expression in AECs through the IRE1α/XBP1 and 
PERK/ATF4 pathways. MLE12 cells were exposed to normoxia (21% O2) or hypoxia (1.5% 
O2) for 24 or 48 hours.  (A) qPCR for CHOP normalized to RPL19 in left panel and western 
blot for CHOP in right panel at 48 hours. (B) Western blots for ATF4, ATF6, IRE1 and β-actin 
at 48 hours. (C) qPCR for ATF4 normalized to RPL19 and spliced XBP1 normalized to 
unspliced XBP1 at 24 hours. Comparisons between groups were made using unpaired, two-
tailed Student’s t-test for A and C. *=p<0.05 compared to MLE12 + 21% O2. (D) MLE12 cells 
were treated with small molecule inhibitor of IRE1 (PCP101) or DMSO (vehicle control) and 
exposed to hypoxia for 48 hours. Western blots for CHOP, IRE1, and ATF4, and RTPCR gel 
showing XBP1 splicing. XBP1u: XBP1 unspliced, XBP1s: XBP1 spliced. (E) Densitometry of 
CHOP normalized to -actin.  (F) MLE12 cells were treated with small molecule inhibitor of 
PERK (GSK2606414) or DMSO (vehicle control) and exposed to hypoxia for 48 hours. qPCRs 
for ATF4 and CHOP normalized to RPL19 and spliced XBP1 normalized to unspliced XBP1.  
(G) MLE12 cells were transfected with HIF1α siRNA or control NT siRNA and exposed to 
hypoxia for 48 hours.  Comparisons between groups were made using unpaired, two-tailed 
Student’s t-test (F) or one way ANOVA with Tukey’s post-hoc test (E,G). *=p<0.05 compared 
to Vehicle + 1.5% O2, **=p<0.05 compared to Vehicle + 21% O2, NS = non-significant. 
Figure 24. siRNA mediated-knockdown of IRE1 and ATF4 followed by evaluation of 
CHOP in MLE12 cells exposed to hypoxia. MLE12 cells were transfected with IRE1, ATF4 
or control non-targeted (NT) siRNA and exposed to hypoxia for 48 hours.  Western blots for 
(A) IRE1, ATF4 and (B) CHOP. -actin is shown as loading control. 
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CHOP regulates hypoxia-induced apoptosis of AECs  
To determine the mechanism through which CHOP regulates hypoxia-induced apoptosis 
of AECs, we transfected MLE12 cells with an siRNA targeting CHOP (or non-targeted control 
siRNA), followed by exposure to 1.5% O2 for 48 hours. We confirmed efficient CHOP 
knockdown and found that CHOP–/– cells were protected from hypoxia-induced cell death (Figure 
26, A and B). To identify the mediators regulated by CHOP in AECs, we utilized the Mouse 
Apoptosis RT2 Profiler PCR Array (Qiagen) to assess mRNA expression of proapoptotic and 
antiapoptotic genes in MLE12 cells treated with CHOP siRNA or nontargeted siRNA and exposed 
to 1.5% O2. Of the 59 genes expressed in MLE12 cells (cycle threshold < 30), 13 were significantly 
downregulated and 1 was upregulated in CHOP–/– cells (Figure 26C and Figure 27). Following 
PCR validation of this set of apoptosis-related genes, 8 genes remained that were differentially 
expressed (all downregulated) in the setting of CHOP deficiency (Table 1).  
  
Figure 25. Efficiency of HIF1α knockdown by siRNA in MLE12 cells. MLE12 cells were 
transfected with HIF1α siRNA or control NT siRNA and exposed to hypoxia for 6 hours. 
qPCR for HIF1α normalized to RPL19. Groups were compared using unpaired, two-tailed 
Student’s t-test. *=p<0.05 compared to NT siRNA + 1.5% O2. 
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Figure 26. CHOP mediates hypoxia-induced apoptosis of AECs through expression of 
apoptosis regulating proteins. MLE12 cells were transfected with CHOP siRNA or non-target 
(NT) siRNA and exposed to hypoxia for 48 hours. (A) Western blot for CHOP. β-actin was 
used as a loading control. (B) Cell death measured by LDH assay. Comparisons between groups 
were made using one way ANOVA with Tukey’s post-hoc test. *=p<0.05 compared to NT 
siRNA + 1.5% O2, **=p<0.05 compared to NT siRNA + 21% O2. (C) Volcano plot showing 
differentially regulated genes (cycle threshold < 30) using the Mouse Apoptosis RT2 Profiler 
PCR Array comparing MLE12 cells treated with CHOP siRNA or NT siRNA followed by 
hypoxia exposure for 48 hours. n = 3 samples in each group.  
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Following PCR validation of this set of apoptosis-related genes, 8 genes remained that were 
differentially expressed (all downregulated) in the setting of CHOP deficiency (Table 1). 
Subsequently, we evaluated these targets in vivo and found that expression of activating 
transcription factor 5 (ATF5), growth arrest and DNA damage inducible α (GADD45A), and 
BCL2-interacting protein 3 like (BNIP3L) were reduced in lungs of CHOP–/– mice compared with 
WT mice after repetitive bleomycin injury (Figure 28), thus validating these targets as potential 
downstream CHOP mediators affecting AEC survival in this model. 
 
Figure 27. Expression of pro-apoptotic mediators in CHOP siRNA or control siRNA 
treated AECs exposed to hypoxia. MLE12 cells were transfected with CHOP siRNA or NT 
control siRNA and exposed to hypoxia for 48 hours. Clustergram analysis of results from 
Mouse Apoptosis RT2 Profiler PCR Array is shown. n = 3 samples per group.   
Table 1. MLE12 cells were transfected with CHOP siRNA or non-target (NT) siRNA and 
exposed to hypoxia for 48 hours. Table showing genes in the Mouse Apoptosis RT2 Profiler 
PCR Array that were differentially regulated by CHOP siRNA treatment and confirmed by 
individual qPCR. n = 3 samples in each group. 
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Figure 28. Expression of CHOP-dependent apoptosis mediators in lungs of CHOP 
deficient mice treated with repetitive bleomycin. Wild type and CHOP-/- mice were studied 
using the repetitive bleomycin model and lungs were harvested 2 weeks after the last dose. 
qPCR for ATF5, GADD45A, and BNIP3L normalized to RPL19.  Groups were compared using 
unpaired two-tailed Student’s t-test. *=p<0.05. 
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DISCUSSION 
 
 We found that (a) in addition to the PERK/ATF4 arm, generally considered to be 
predominant in CHOP activation, the IRE1α/XBP1 arm of the UPR is also necessary for hypoxia-
induced upregulation of CHOP in AECs, and (b) CHOP upregulates expression of several 
apoptosis-related genes in AECs following exposure to hypoxia, including GADD45A, ATF5, and 
BNIP3L, which we verified in lungs of CHOP–/– mice after recurrent bleomycin injury. 
In our studies, CHOP expression in AECs was unrelated to HIF signaling but was induced 
by ER stress through the IRE1α/XBP1 and PERK/ATF4 pathways in hypoxia. In disease models, 
the PERK pathway has been implicated in liver fibrosis (156), and the IRE1α pathway has been 
reported to regulate both liver and skin fibrosis (157-159). Together with our studies, these data 
indicate that these UPR pathways may be most relevant for regulating fibrotic remodeling. 
Our data showed that CHOP induces apoptosis of AECs in hypoxia, likely via expression 
of CHOP target genes. Although the molecular mechanisms underlying CHOP-induced apoptosis 
may be context dependent, our studies showed that CHOP upregulates expression of numerous 
apoptosis-related genes in AECs following exposure to hypoxia, including GADD45A, ATF5, and 
BNIP3L. GADD45A can regulate cell cycle checkpoints, apoptosis, and DNA repair by 
contributing to activation of p53 (160), a protein that is upregulated in AECs in IPF (161). ATF5 
has been identified as a direct downstream target of CHOP in mouse embryonic fibroblasts and 
has been reported to cooperate with CHOP for full induction of a specific subset of downstream 
genes (162). BNIP3L functions in B cell lymphoma 2–mediated (Bcl-2–mediated) cell death, 
production of reactive oxygen species, and mitophagy (163). While the effect of CHOP may be 
multifactorial, further work is needed to precisely define the pathways through which CHOP 
regulates AEC apoptosis during lung fibrosis. 
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Taken together, these studies have furthered our understanding of regulation of CHOP and 
the molecular mediators involved in CHOP-induced apoptosis in AECs in hypoxia. 
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V. THE ROLE OF HYPOXIA-INDUCIBLE FACTOR (HIF) IN LUNG 
FIBROSIS 
 
Hypoxia mediates a pro-fibrotic phenotype in alveolar epithelial cells 
 We wondered whether hypoxia could influence the expression of pro-fibrotic mediators in 
AECs. Therefore, we exposed MLE12 cells to hypoxia (1.5% O2) or normoxia (21% O2) for 48 
hours and measured the expression of several pro-fibrotic mediators including cysteine-rich 
angiogenic inducer 61-CYR61 (CCN1), connective tissue growth factor (CTGF/CCN2), 
collagen1, platelet derived growth factor B (PDGFB), transforming growth factor  (TGFβ), and 
vascular endothelial growth factor (VEGF) by qPCR. We found that exposure to hypoxia led to a 
significant increase in expression of each of these mediators (Figure 29). 
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HIF signaling regulates expression of pro-fibrotic mediators in alveolar 
epithelial cells 
 We tested for induction of HIFs in MLE12 cells exposed to hypoxia (Figure 30). We 
exposed MLE12 cells to hypoxia (1.5% O2) or normoxia (21% O2) for 6, 24, or 48 hours. By 
western blotting for HIF1 on cell lysates, we found that exposure to hypoxia stabilized HIF1 
with maximum stabilization at 6 hours (Figure 30A). Also, immunofluorescence staining showed 
prominent expression of both HIF1α and HIF2α in the nuclei of MLE12 cells exposed to hypoxia 
at this time point (Figure 30B). To evaluate for HIF transcriptional activity, we generated stable 
MLE12 cells containing a hypoxia response element (HRE) driven luciferase construct.  These 
cells were then exposed to hypoxia (1.5% O2) or maintained in normoxia (21% O2) for 2, 4, 6, or 
15 hours. Consistent with our findings of HIF stabilization, reporter cells exposed to hypoxia 
Figure 29. Hypoxia induces expression of pro-fibrotic mediators in AECs. MLE12 cells 
were exposed to normoxia or hypoxia for 48 hours. qPCRs for CCN1, CTGF, Collagen-1, 
PDGFB, TGF, and VEGF normalized to RPL19. Comparisons between groups were made 
using unpaired, two-tailed Student’s t-test. *=p<0.05 compared to normoxia.  
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showed HRE-dependent luciferase activity (reflective of transcriptional activity of HIF) that 
peaked at 6 hours (Figure 30C).  
 
 
Next, we evaluated the effect of HIF signaling on the expression of pro-fibrotic mediators 
in AECs. We transfected MLE12 cells with siRNA against HIF1 or control non-target siRNA 
and exposed them to hypoxia (1.5% O2) or normoxia (21% O2) for 48 hours. Following hypoxia, 
cells with HIF1α deficiency showed a significant decrease in expression of pro-fibrotic mediators 
VEFG and PDGFB (Figure 31). Together, these studies suggest that hypoxia increases expression 
of pro-fibrotic mediators in AECs, at least some of which are regulated through HIF signaling.  
Figure 30. Exposure to hypoxia induces HIF signaling in AECs peaking at 6 hours. (A) 
MLE12 cells were exposed to hypoxia or normoxia for for 6. 24, or 48 hours. Western blotting 
for HIF1 −actin was used as loading control.  (B) MLE12 were exposed to hypoxia or 
normoxia for 6 hours and immunofluorescence staining was performed with rabbit antibodies 
to HIF1α or HIF2α, Cy3 conjugated secondary antibodies, and DAPI. Red nuclei indicate 
positive staining (C) Stably transfected MLE12 cells were generated with a hypoxia responsive 
element (HRE)-luciferase construct using puromycin selection. Reporter cells were then 
exposed to hypoxia or normoxia for 2, 4, 6, or 15 hours. Luciferase activity was measured as 
relative light units (RLU). 
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Epithelial HIF signaling is not essential for mediating the effects of hypoxia on 
lung fibrosis in the ‘bleomycin + hypoxia’ model 
To evaluate whether epithelial HIF signaling affects lung fibrosis in mice, we generated 
mice with lung epithelial cell–specific deletion of HIF1α and HIF2α. Epithelial HIF1/2-deficient 
(HIF1/2Δ/Δ) mice and littermate controls (HIF1/2fl/fl) were treated with bleomycin (0.04 units), 
followed by exposure to 14% O2 or 21% O2 between day 7 and 21. We found that despite 
substantial HIF activation (Figure 32), epithelial HIF1/2 deletion did not alter lung fibrosis 
(Figure 33) in mice treated with bleomycin followed by exposure to hypoxia. 
Figure 31. HIF signaling regulates expression of pro-fibrotic mediators VEGF and 
PDGFB exposed to hypoxia. MLE12 cells were transfected with HIF1α siRNA or non-
targeted (NT) siRNA and exposed to hypoxia or normoxia for 48 hours. qPCRs for VEGF and 
PDGFB normalized to RPL19. *p<0.05 compared to NT siRNA.  
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Figure 32. Evaluation of HIF1α in the bleomycin + hypoxia model. Mice were treated with 
intratracheal bleomycin (0.04 units) followed 7 days later by exposure to 14% O2 for an 
additional 14 days or maintained in 21% O2. Lungs were harvested at 21 days post-bleomycin. 
(A) Representative immunohistochemistry for HIF1α on lung sections. (B) Western blot for 
HIF1 in lung tissue lysates. β-actin was used as a loading control. Comparisons between 
groups were made using unpaired two-tailed Student’s t-test. *=p<0.05. 
A B 
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Figure 33. Epithelial HIF deficient mice are not protected from exaggerated lung fibrosis 
induced by exposure to hypoxia. Mice with targeted deletion of HIF1/2 in lung epithelium 
(HIF1/2Δ/Δ) and controls (HIF1/2fl/fl) were studied in the bleomycin + hypoxia model. (A) 
Representative Masson’s trichrome staining on lung sections. Scale bars: 800 µm.  (B) 
Morphometric evaluation of fibrosis at 21 days after bleomycin injection. (C) Total soluble 
collagen in right lower lobe (RLL) by sircol assay. Comparisons between groups were made 
using one way ANOVA with Tukey’s post-hoc test. NS = non-significant. 
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Although epithelial HIF signaling did not protect from lung fibrosis in mice treated with 
bleomycin followed by exposure to hypoxia, we wondered whether HIF signaling could regulate 
the expression of pro-fibrotic mediators in this model. Therefore, we performed qPCRs for TGF, 
CTGF, PDGFB and VEGF on mRNA isolated from lung lysates of HIF1/2Δ/Δ and HIF1/2fl/fl mice. 
However, similar to our finding of no difference in fibrosis between HIF1/2Δ/Δ and HIF1/2fl/fl mice, 
we found no significant difference in expression of any of the pro-fibrotic mediators in HIF1/2Δ/Δ 
mice compared to HIF1/2fl/fl mice (Figure 34).  
 
 
 
 
 
 
 
 
 
In summary, these studies demonstrate that epithelial HIF is not essential in mediating the 
effects of hypoxia on lung fibrosis in the ‘bleomycin + hypoxia’ model.  
 
 
Figure 34. Epithelial HIF deficient mice and littermate controls have similar expression 
of pro-fibrotic mediators after bleomycin treatment followed by exposure to hypoxia. 
Mice with targeted deletion of HIF1/2 in lung epithelium (HIF1/2Δ/Δ) and controls (HIF1/2fl/fl) 
were studied in the bleomycin + hypoxia model. qPCR for TGF, CTGF, PDGFB and VEGF 
on mRNA isolated from lung lysates was performed. RPL19 was used for normalization. 
Comparisons between groups were made using unpaired two-tailed Student’s t-test. 
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Epithelial HIF mediates lung fibrosis after repetitive bleomycin injury to the 
lungs 
Next, we performed experiments using repetitive i.t. bleomycin in HIF1/2Δ/Δ and HIF1/2fl/fl 
mice to determine whether epithelial HIF is an important profibrotic mediator in this model 
(Figure 35). In these studies, we observed significant protection of HIF1/2Δ/Δ mice from 
development of lung fibrosis, with a marked reduction in fibrotic area (Figure 35A), reduced 
hyperplastic AECs (Figure 35B), reduced collagen content (Figure 35C), and decreased collagen-
1 mRNA expression (Figure 35D).  
Figure 35. Epithelial HIF signaling plays an important role in mediating lung fibrosis after 
repetitive bleomycin injury.  HIF1/2Δ/Δ and HIF1/2fl/fl mice were studied using the repetitive 
bleomycin model and lungs were harvested 2 weeks after the last dose. (A) Representative 
Masson’s trichrome stained lung sections. Scale bars: 800 µm. (B) Evaluation of fibrosis by 
morphometry.  (C) Quantification of hyperplastic AECs. (D) Quantification of total soluble 
collagen in right lower lobe (RLL) by sircol assay. (E) qPCR for collagen-1 from mRNA 
isolated from whole lung lysate. RPL19 was used for normalization. Comparisons between 
groups were made using unpaired, two-tailed Student’s t-test (A and B) or one way ANOVA 
with Tukey’s post-hoc test (C and D). *=p<0.05 compared to HIF1/2fl/fl  + rep bleo, **=p<0.05 
compared to untreated HIF1/2fl/fl .  
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DISCUSSION 
 
 These studies show that while epithelial HIF signaling does not affect lung fibrosis after 
single dose bleomycin treatment or bleomycin treatment followed by exposure to hypoxia, it 
appears to play an important role in progression of fibrosis after repetitive bleomycin injury in 
mice.  
 Hypoxia and/or HIF signaling have been implicated in regulating expression of pro-fibrotic 
mediators including collagen (122). In our work, we found that exposure to hypoxia increases the 
expression of several pro-fibrotic mediators (CCN1, CTGF, collagen1, PDGFB, VEGF, and 
TGF) of which few (PDGFB and VEGF) are regulated by HIF in AECs. However, epithelial HIF 
targeting did not affect fibrosis in mice treated with a single dose of bleomycin followed by 
exposure to normoxia or hypoxia. Similar to this observation, we had previously found that 
endothelial HIF deletion reduces pulmonary hypertension but not lung fibrosis following IP 
bleomycin treatment in mice (164). Contrary to our observation in the bleomycin + hypoxia model, 
in preliminary studies with epithelial HIF targeted mice in the repetitive bleomycin model, we 
found that epithelial HIF deficiency leads to reduced lung fibrosis following repetitive bleomycin 
injury. Taken together, these findings suggest that the effect of epithelial HIF signaling on lung 
fibrosis is likely dependent on the nature of injury and the stage of the disease; while epithelial 
HIF does not affect disease phenotype in a setting of acute injury, it seems to play an important 
role in progression of the disease in a setting of chronic/repetitive injury. Additional investigations 
regarding the mechanisms by which HIF signaling regulates lung remodeling are warranted.   
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VI. CONCLUDING REMARKS AND FUTURE DIRECTIONS 
 
Our studies described in this dissertation show that following persistent injury to the lungs, 
localized hypoxia in AECs in areas of alveolar collapse augments ER stress. The ER stress-
downstream effector CHOP plays a critical role in progression of lung fibrosis, likely through 
increasing apoptosis of AECs and impairing re-epithelialization. While HIF, the primary mediator 
of cellular responses to hypoxia, does not seem important in mediating the effects of hypoxia on 
ER stress, it may act through independent pathways to impact lung fibrosis after repetitive 
bleomycin injury. At a mechanistic level, we investigated the regulation and downstream function 
of CHOP in AECs exposed to hypoxia. We found that in addition to the upstream UPR pathway 
PERK/ATF4, commonly implicated in induction of CHOP, the IRE1-XBP1 arm of the UPR also 
plays an important role in regulating CHOP in AECs in hypoxia. Furthermore, we identified 
GADD45A, ATF5, and BNIP3L as important potential downstream-mediators of CHOP-induced 
apoptosis of AECs in hypoxia. Based on these findings, we propose a model (Figure 36) showing 
potential mechanisms by which localized tissue hypoxia augments fibrotic remodeling in the lung. 
Together, these findings represent an important advance in understanding the mechanisms linking 
hypoxia, ER stress, epithelial dysfunction, and progressive lung fibrosis.  
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Our findings support the idea that hypoxia can develop in areas of alveolar collapse and 
consolidation through reduced ventilation, hypoxic vasoconstriction, and increased oxygen 
demand. Increased expression of a repertoire of hypoxia-inducible genes has been reported in IPF 
lungs and in single-cell analysis of AECs in IPF (65-67), consistent with our findings of increased 
expression of markers of hypoxia in lung tissue of IPF patients. In experimental models, regions 
of hypoxia have been observed in lungs of rats following radiation-induced injury (165) and in 
Figure 36. Model showing that tissue hypoxia leads to type II AEC dysfunction and 
augments lung fibrosis through ER stress and HIF signaling pathways. Exposure to 
repetitive injurious stimuli causes damage to the distal lung. Alveolar collapse, hypoxic 
vasoconstriction, and matrix deposition lead to inefficient ventilation and perfusion in localized 
areas giving rise to tissue hypoxia. Hypoxia causes HIF stabilization and augments ER stress 
in type II AECs. Specifically, ER stress-mediators PERK/ATF4 and IRE1/XBP1 contribute to 
induction of transcription factor CHOP. Downstream targets of HIF and CHOP favor a pro-
fibrotic type II AEC phenotype. Ongoing dysfunction of type II AECs leads to impaired re-
epithelialization and progressive fibrosis.  
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injured lungs of mice following H1N1 influenza infection (67). Future studies can aim to further 
determine the specific contribution of localized tissue hypoxia in the injured lung parenchyma to 
progression of lung fibrosis.  
Our data with CHOP deficient and HIF targeted mice point to an important distinction 
between the single dose bleomycin model, most commonly used in the IPF field, and the repetitive 
bleomycin model. While the effects of CHOP and HIF on lung fibrosis were not apparent in the 
single dose bleomycin model where localized hypoxia and ER stress in the lung parenchyma were 
minimal, both CHOP and HIF proved to be important in mediating lung fibrosis in the repetitive 
bleomycin model. Since repetitive injuries in the lung parenchyma are thought to underlie 
progressive fibrosis in IPF, factors identified as important in multiple-injury models may have 
added relevance when designing new therapeutic strategies for humans. This idea is further 
supported by our findings of increased expression of hypoxia markers and CHOP in hyperplastic 
type II AECs in IPF lungs. Based on these observations, in future studies, it would be important to 
pay close attention to the choice of animal models while trying to answer questions related to 
pathogenesis of lung fibrosis.  
CHOP is a multifunctional transcription factor that regulates ER stress–induced apoptosis 
(151). In our studies, the effect of CHOP on fibrosis was mirrored by its effects on AEC apoptosis, 
thus implicating CHOP-induced AEC apoptosis as an important mechanism influencing fibrosis 
severity. Although we have focused on the role of CHOP in mediating ER stress–induced 
apoptosis, JNK and caspase-4/12 are additional ER stress–induced mediators that could affect 
AEC apoptosis and fibrosis (166-168). Additional studies will be needed to delineate the role of 
those pathways in lung fibrosis.  
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In addition to apoptosis, CHOP can regulate a variety of cellular processes, such as 
differentiation, polarization, and inflammatory signaling, through direct transcriptional regulation 
and interactions with other C/ EBP family members (36, 39, 151, 169-171). In our studies, we 
found that while CHOP does not have a significant effect on inflammatory cells (except 
neutrophils) , it has a potential role in multiple pro-fibrotic processes in AECs including epithelial 
differentiation, growth factor responses, and cell migration. Future investigations will be required 
to determine the effect of CHOP on these pro-fibrotic responses. Also, in current studies aimed at 
understanding the role of CHOP in AECs in lung fibrosis, we used whole body CHOP knockout 
mice. While our studies with L188Q SFTPC/CHOP–/– mice showed that CHOP is required for 
mediating lung fibrosis when ER stress is induced specifically in AECs, future studies with 
epithelial CHOP targeted mice will be needed to more precisely define the role of epithelial CHOP 
in lung fibrosis.  
ER stress can skew macrophages both towards the classically activated (M1) or 
alternatively activated (M2) phenotypes depending on the pathophysiological context. In our 
studies, we did not observe induction of CHOP in macrophages in WT mice on exposure of 
bleomycin-treated mice to hypoxia. Consistent with lack of induction of CHOP, flow cytometry 
experiments quantifying pulmonary macrophages in WT and CHOP-/- mice in our fibrosis models 
showed that CHOP deficiency did not impact alveolar or interstitial macrophages (except a 
decrease in interstitial macrophages in mice treated with bleomycin and exposed at day 7 post-
bleomycin to hypoxia for 3 days). On evaluation of the effect of CHOP on polarization of 
macrophages, we did not find a clear M1/M2 phenotype shift between WT and CHOP-/- mice in 
the bleomycin + hypoxia model at either day 10 or day 21 post-bleomycin; however, we did 
observe a significant decrease in expression of M1 marker IL-6 and M2 marker Ym1 in CHOP-/- 
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mice compared to WT mice at day 21 post-bleomycin and a decrease in expression of M2 marker 
arginase in CHOP-/- mice compared to WT mice at day 10 post-bleomycin. Taken together, while 
we found minimal impact of CHOP on phenotype of macrophages in this body of work, further 
experiments are warranted to determine the effect of ER stress/CHOP in macrophages on lung 
fibrosis. For example, RNA sequencing analyses comparing the transcriptional signature of 
macrophages isolated from WT mice and mice with macrophage specific deletion of CHOP (e.g. 
LysMCre.CHOP-/- mice) in experimental models of fibrosis will provide information on potential 
pro-fibrotic effects of CHOP on macrophages in the lungs.  
While our studies with epithelial HIF targeted mice suggest a potential role for HIF in 
mediating lung fibrosis after recurrent injury to the lungs, additional investigations will be needed 
to precisely define the mechanisms by which HIF signaling regulates lung fibrosis. Recently, Xi 
et al. demonstrated that HIF1 drives persistent Notch activity in lineage negative alveolar 
progenitor cells, leading to impaired epithelial regeneration in the lung parenchyma in an H1N1 
inﬂuenza injury model (67). Given that impaired re-epithelialization is critical in pathogenesis of 
lung fibrosis, it is tempting to speculate about a potential role of the HIF1-Notch axis in impaired 
epithelial regeneration in lung fibrosis. Also, it has been suggested that HIF may interact with the 
UPR pathways through mammalian target of rapamycin (mTOR) signaling (39); additional studies 
will be needed to evaluate these potential interactions in AECs in lung injury-repair and 
remodeling. We used mice with epithelial deficiency of both HIF1 and HIF2 in our studies; 
however, given that HIF1 and HIF2 activate specific subsets of genes and can have opposing 
functions (172), future studies with specific HIF isoforms are warranted. Also, further work will 
be needed to understand the pro-fibrotic effects of HIF1 and HIF2 on AECs. Furthermore, the 
role of HIF in different cell types in lung fibrosis remains to be determined. For example, 
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HIF1 has been implicated in polarization, migration and apoptosis of macrophages (Ref); future 
experiments with LysMCre.HIF1-/- and LysMCre.HIF2-/- mice will help in understanding the 
effect of HIF signaling in macrophages on lung fibrosis.  
In summary, we have furthered knowledge in this area by discovering that ER stress is 
mechanistically linked to lung fibrosis through CHOP in three distinct multiple injury-induced 
lung fibrosis mouse models, and demonstrating that CHOP is a critical molecular mediator of ER 
stress–induced apoptosis and may also regulate other important profibrotic functions of AECs in 
lung fibrosis. Based on these findings, CHOP and its downstream targets may be attractive targets 
for novel therapeutic strategies in IPF. Furthermore, our work shows that localized hypoxia in 
areas of parenchymal damage could explain the etiology of ER stress in lung fibrosis, and suggests 
a potential role for epithelial HIF signaling in lung fibrosis. Taken together, this body of work 
advances our understanding of the role of localized hypoxia and ER stress in the pathophysiology 
of lung fibrosis.  
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